

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16

**The genetics of blood pressure regulation and its target organs from
association studies in 342,415 individuals**

1 **AUTHORS**

2 Georg B. Ehret^{1,2*}, Teresa Ferreira^{3*}, Daniel I. Chasman^{4,5}, Anne U. Jackson^{6,7}, Ellen M. Schmidt⁸, Toby
3 Johnson^{9,10}, Gudmar Thorleifsson¹¹, Jian'an Luan¹², Lousie A. Donnelly¹³, Stavroula Kanoni¹⁴, Ann-Kristin
4 Petersen¹⁵, Vasyli Pihur¹, Rona J. Strawbridge^{16,17}, Dmitry Shungin^{18,19,20}, Maria F. Hughes²¹, Osorio
5 Meirelles²², Marika Kaakinen²³, Nabila Bouatia-Naji^{24,25}, Kati Kristiansson^{26,27}, Sonia Shah²⁸, Marcus E.
6 Kleber²⁹, Xiuqing Guo³⁰, Leo-Pekka Lyytikäinen^{31,32}, Cristiano Fava^{33,34}, Niclas Eriksson³⁵, Ilja M. Nolte³⁶,
7 Patrik K. Magnusson³⁷, Elias L. Salfati³⁸, Loukianos S. Rallidis³⁹, Elizabeth Theusch⁴⁰, Andrew J.P. Smith⁴¹,
8 Lasse Folkersen¹⁶, Kate Witkowska^{9,42}, Tune H. Pers^{43,44,45,46,47}, Roby Joehanes⁴⁸, Stuart K. Kim⁴⁹, Lazaros
9 Lataniotis¹⁴, Rick Jansen⁵⁰, Andrew D. Johnson^{48,51}, Helen Warren^{9,42}, Young Jin Kim⁵², Wei Zhao⁵³, Ying
10 Wu⁵⁴, Bamidele O. Tayo⁵⁵, Murielle Bochud⁵⁶, CHARGE-EchoGen consortium⁵⁷, CHARGE-HF
11 consortium⁵⁷, Wellcome Trust Case Control Consortium⁵⁷, Devin Absher⁵⁸, Linda S. Adair⁵⁹, Najaf Amin⁶⁰,
12 Dan E. Arking¹, Tomas Axelsson⁶¹, Damiano Baldassarre^{62,63}, Beverley Balkau⁶⁴, Stefania Bandinelli⁶⁵,
13 Michael R. Barnes^{14,42}, Inês Barroso^{66,67,68}, Stephen Bevan⁶⁹, Joshua C. Bis⁷⁰, Gyda Bjornsdottir¹¹, Michael
14 Boehnke^{6,7}, Eric Boerwinkle⁷¹, Lori L. Bonnycastle⁷², Dorret I. Boomsma⁷³, Stefan R. Bornstein⁷⁴, Morris J.
15 Brown⁷⁵, Michel Burnier⁷⁶, Claudia P. Cabrera^{9,42}, John C. Chambers^{77,78,79}, I-Shou Chang⁸⁰, Ching-Yu
16 Cheng^{81,82,83}, Peter S. Chines⁷², Ren-Hua Chung⁸⁴, Francis S. Collins⁷², John M. Connell⁸⁵, Angela
17 Döring^{86,87}, Jean Dallongeville⁸⁸, John Danesh^{89,66,90}, Ulf de Faire⁹¹, Graciela Delgado²⁹, Anna F.
18 Dominiczak⁹², Alex S.F. Doney¹³, Fotios Drenos⁴¹, Sarah Edkins⁶⁶, John D. Eicher^{48,51}, Roberto Elosua⁹³,
19 Stefan Enroth^{94,95}, Jeanette Erdmann^{96,97}, Per Eriksson¹⁶, Tonu Esko^{98,99,100}, Evangelos Evangelou^{77,101},
20 Alun Evans²¹, Tove Fall¹⁰², Martin Farrall^{3,103}, Janine F. Felix¹⁰⁴, Jean Ferrières¹⁰⁵, Luigi Ferrucci¹⁰⁶, Myriam
21 Fornage¹⁰⁷, Terrence Forrester¹⁰⁸, Nora Franceschini¹⁰⁹, Oscar H. Franco Duran¹⁰⁴, Anders Franco-
22 Cereceda¹¹⁰, Ross M. Fraser^{111,112}, Santhi K. Ganesh¹¹³, He Gao⁷⁷, Karl Gertow^{16,17}, Francesco
23 Gianfagna^{114,115}, Bruna Gigante⁹¹, Franco Giulianini⁴, Anuj Goel^{3,103}, Alison H. Goodall^{116,117}, Mark O.
24 Goodarzi¹¹⁸, Mathias Gorski^{119,120}, Jürgen Gräßler¹²¹, Christopher Groves¹²², Vilmundur Gudnason^{123,124},
25 Ulf Gyllensten^{94,95}, Göran Hallmans¹⁸, Anna-Liisa Hartikainen^{125,126}, Maija Hassinen¹²⁷, Aki S. Havulinna²⁶,
26 Caroline Hayward¹²⁸, Serge Hercberg¹²⁹, Karl-Heinz Herzig^{130,131,132}, Andrew A. Hicks¹³³, Aroon D.
27 Hingorani²⁸, Joel N. Hirschhorn^{43,44,45,134}, Albert Hofman^{104,135}, Jostein Holmen¹³⁶, Oddgeir Lingaas
28 Holmen^{136,137}, Jouke-Jan Hottenga⁷³, Phil Howard⁴¹, Chao A. Hsiung⁸⁴, Steven C. Hunt^{138,139}, M. Arfan
29 Ikram^{104,140,141}, Thomas Illig^{142,143,144}, Carlos Iribarren¹⁴⁵, Richard A. Jensen^{70,146}, Mika Kähönen¹⁴⁷, Hyun
30 Kang^{6,7}, Sekar Kathiresan^{148,149,150,45,151}, Brendan J. Keating^{152,153}, Kay-Tee Khaw¹⁵⁴, Yun Kyoung Kim⁵², Eric
31 Kim¹⁵⁵, Mika Kivimaki²⁸, Norman Klopp^{142,143}, Genovefa Kolovou¹⁵⁶, Pirjo Komulainen¹²⁷, Jaspal S.
32 Kooner^{157,78,79}, Gulum Kosova^{149,148,100}, Ronald M. Krauss¹⁵⁸, Diana Kuh¹⁵⁹, Zoltan Kutalik^{160,161}, Johanna

1 Kuusisto¹⁶², Kirsti Kvaløy¹³⁶, Timo A Lakka^{163,127,164}, Nanette R. Lee^{165,166}, I-Te Lee^{167,168}, Wen-Jane Lee¹⁶⁹,
 2 Daniel Levy^{48,170}, Xiaohui Li³⁰, Kae-Woei Liang^{171,172}, Honghuang Lin^{173,48}, Li Lin², Jaana Lindström²⁶,
 3 Stéphane Lobbens^{174,175,176}, Satu Männistö²⁶, Gabriele Müller¹⁷⁷, Martina Müller-Nurasyid^{15,178,179},
 4 François Mach², Hugh S. Markus¹⁸⁰, Eirini Marouli^{14,181}, Mark I. McCarthy¹²², Colin A. McKenzie¹⁰⁸, Pierre
 5 Meneton¹⁸², Cristina Menni¹⁸³, Andres Metspalu⁹⁸, Vladan Mijatovic¹⁸⁴, Leena Moilanen^{185,186}, May E.
 6 Montasser¹⁸⁷, Andrew D. Morris¹³, Alanna C. Morrison¹⁸⁸, Antonella Mulas¹⁸⁹, Ramaiah Nagaraja²²,
 7 Narisu Narisu⁷², Kjell Nikus^{190,191}, Christopher J. O'Donnell^{192,48,151}, Paul F. O'Reilly¹⁹³, Ken K. Ong¹², Fred
 8 Paccaud⁵⁶, Cameron D. Palmer^{194,195,45}, Afshin Parsa¹⁸⁷, Nancy L. Pedersen³⁷, Brenda W. Penninx^{196,197,198},
 9 Markus Perola^{26,27,98}, Annette Peters⁸⁷, Neil Poulter¹⁹⁹, Peter P. Pramstaller^{133,200,201}, Bruce M.
 10 Psaty^{70,202,203,204}, Thomas Quertermous³⁸, Dabeeru C. Rao²⁰⁵, Asif Rasheed²⁰⁶, N William N.W.R.
 11 Rayner^{122,3,66}, Frida Renström^{19,207,18}, Rainer Rettig²⁰⁸, Kenneth M. Rice²⁰⁹, Robert Roberts^{210,211}, Lynda M.
 12 Rose⁴, Jacques Rossouw²¹², Nilesh J. Samani^{116,213}, Serena Sanna¹⁸⁹, Jouko Saramies²¹⁴, Heribert
 13 Schunkert^{215,216,217,218}, Sylvain Sebert^{219,131,164}, Wayne H.-H. Sheu^{167,168,220}, Young-Ah Shin⁵², Xueling
 14 Sim^{6,7,221}, Johannes H. Smit¹⁹⁶, Albert V. Smith^{123,124}, Maria X. Sosa¹, Tim D. Spector¹⁸³, Alena
 15 Stančáková²²², Alice Stanton²²³, Kathleen E. Stirrups^{14,224}, Heather M. Stringham^{6,7}, Johan Sundstrom⁶¹,
 16 Amy J. Swift⁷², Ann-Christine Syvänen⁶¹, E-Shyong Tai^{225,82,221}, Toshiko Tanaka¹⁰⁶, Kirill V. Tarasov²²⁶,
 17 Alexander Teumer²²⁷, Unnur Thorsteinsdottir^{11,124}, Martin D. Tobin²²⁸, Elena Tremoli^{62,63}, Andre G.
 18 Uitterlinden^{104,229}, Matti Uusitupa^{230,231}, Ahmad Vaez^{36,232}, Dhananjay Vaidya²³³, Cornelia M. van
 19 Duijn^{104,234}, Erik P.A. van Iperen^{235,236}, Ramachandran S. Vasani^{48,237,238}, Germaine C. Verwoert¹⁰⁴, Jarmo
 20 Virtamo²⁶, Veronique Vitart¹²⁸, Benjamin F. Voight^{45,239}, Peter Vollenweider²⁴⁰, Aline Wagner²⁴¹, Louise V.
 21 Wain²²⁸, Nicholas J. Wareham¹², Hugh Watkins^{3,103}, Alan B. Weder²⁴², Harm-Jan Westra²⁴³, Rainford
 22 Wilks²⁴⁴, Tom Wilsgaard^{245,246}, James F. Wilson^{111,128}, Tien Y. Wong^{81,82,83}, Tsun-Po Yang^{14,247}, Jie Yao³⁰,
 23 Loic Yengo^{174,175,176}, Weihua Zhang^{77,78}, Jing Hua Zhao¹², Xiaofeng Zhu²⁴⁸, Pascal Bovet^{249,56}, Richard S.
 24 Cooper⁵⁵, Karen L. Mohlke⁵⁴, Danish Saleheen^{250,206}, Jong-Young Lee⁵², Paul Elliott^{77,251}, Hincio J.
 25 Gierman^{49,252}, Cristen J. Willer^{8,253,254}, Lude Franke²⁵⁵, G Kees Hovingh²⁵⁶, Kent D. Taylor³⁰, George
 26 Dedoussis¹⁸¹, Peter Sever¹⁹⁹, Andrew Wong¹⁵⁹, Lars Lind⁶¹, Themistocles L. Assimes³⁸, Inger Njølstad^{245,246},
 27 Peter EH. Schwarz⁷⁴, Claudia Langenberg¹², Harold Snieder³⁶, Mark J. Caulfield^{9,42}, Olle Melander³³,
 28 Markku Laakso¹⁶², Juha Saltevo²⁵⁷, Rainer Rauramaa^{127,164}, Jaakko Tuomilehto^{26,258,259,260}, Erik
 29 Ingelsson^{102,3}, Terho Lehtimäki^{31,32}, Kristian Hveem¹³⁶, Walter Palmas²⁶¹, Winfried März^{262,263}, Meena
 30 Kumari²⁸, Veikko Salomaa²⁶, Yii-Der I. Chen³⁰, Jerome I. Rotter³⁰, Philippe Froguel^{174,175,176,23}, Marjo-Riitta
 31 Jarvelin^{219,131,264,251}, Edward G. Lakatta²²⁶, Kari Kuulasmaa²⁶, Paul W. Franks^{19,207,18}, Anders Hamsten^{16,17},
 32 H.-Erich Wichmann^{86,179,265}, Colin N.A. Palmer¹³, Kari Stefansson^{11,124}, Paul M Ridker^{4,5}, Ruth J.F.

1 Loos^{12,266,267}, Aravinda Chakravarti¹, Panos Deloukas^{14,268}, Andrew P. Morris^{269,3#}, Christopher Newton-
2 Cheh^{148,149,45,100#}, Patricia B. Munroe^{9,42#}

3 * These authors contributed equally to this work.

4 # These authors jointly supervised this work.

5 Corresponding authors: Christopher Newton-Cheh (cnewtoncheh@mgh.harvard.edu) and Patricia B.
6 Munroe (p.b.munroe@qmul.ac.uk).

7

1 **AUTHOR AFFILIATIONS**

- 2 1. Center for Complex Disease Genomics, McKusick-Nathans Institute of Genetic Medicine, Johns
3 Hopkins University School of Medicine, Baltimore, MD 21205, USA
4 2. Cardiology, Department of Medicine, Geneva University Hospital, Rue Gabrielle-Perret-Gentil 4, 1211
5 Geneva 14, Switzerland
6 3. Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, OX3 7BN, UK
7 4. Division of Preventive Medicine, Brigham and Women's Hospital, 900 Commonwealth Ave. East,
8 Boston, MA 02215, USA
9 5. Harvard Medical School, Boston, MA 02115, USA
10 6. Department of Biostatistics, University of Michigan, Ann Arbor, MI 48109, USA
11 7. Center for Statistical Genetics, University of Michigan, Ann Arbor, MI 48109, USA
12 8. Department of Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, MI
13 48109, USA
14 9. Clinical Pharmacology, William Harvey Research Institute, Queen Mary University of London, London,
15 EC1M 6BQ, UK
16 10. GlaxoSmithKline, Gunnels Wood Road, Stevenage SG1 2NY, UK
17 11. deCODE Genetics/Amgen, Inc., Reykjavik, Iceland
18 12. MRC Epidemiology Unit, University of Cambridge School of Clinical Medicine, Institute of Metabolic
19 Science, Cambridge Biomedical Campus, Cambridge, CB2 0QQ, UK
20 13. Medical Research Institute, University of Dundee, Ninewells Hospital and Medical School, Dundee,
21 DD1 9SY, UK
22 14. William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen
23 Mary University of London, London, UK
24 15. Institute of Genetic Epidemiology, Helmholtz Zentrum München, Neuherberg 85764, Germany
25 16. Cardiovascular Research Unit, Center for Molecular Medicine L8:03, Department of Medicine,
26 Karolinska Institutet, 171 76 Stockholm, Sweden
27 17. Center for Molecular Medicine, Karolinska University Hospital Solna, Stockholm, Sweden
28 18. Department of Public Health and Clinical Medicine, Umeå University, Sweden
29 19. Department of Clinical Sciences, Genetic and Molecular Epidemiology Unit, Skåne University
30 Hospital Malmö, SE-205 02 Malmö, Sweden
31 20. Department of Odontology, Umeå University, Sweden
32 21. Centre of Excellence for Public Health, Queens University Belfast, Grosvenor Road, Belfast BT126JP,
33 UK
34 22. Laboratory of Genetics, Intramural Research Program, National Institute on Aging, National
35 Institutes of Health, Baltimore, Maryland 21224, USA
36 23. Department of Genomics of Common Disease, School of Public Health, Imperial College London,
37 Hammersmith Hospital, London, UK
38 24. INSERM UMR970, Paris Cardiovascular Research Center PARCC, 56 rue Leblanc, 75015 Paris, France
39 25. University Paris-Descartes, Sorbonne Paris Cité, 12 rue de l'École de médecine, F-75006 Paris, France
40 26. National Institute for Health and Welfare, FI-00271 Helsinki, Finland
41 27. Institute for Molecular Medicine Finland FIMM, University of Helsinki, 00290 Helsinki, Finland
42 28. Genetic Epidemiology Group, Dept. Epidemiology and Public Health, UCL, London, WC1E 6BT, UK
43 29. Vth Department of Medicine, Medical Faculty Mannheim, Heidelberg University, Theodor-Kutzer-
44 Ufer 1-3, 68167 Mannheim, Germany
45 30. Institute for Translational Genomics and Population Sciences, Los Angeles Biomedical Research
46 Institute at Harbor-UCLA Medical Center, 1124 W. Carson Street, Torrance, CA 90502, USA
47 31. Department of Clinical Chemistry, Fimlab Laboratories, Tampere 33520, Finland

- 1 32. Department of Clinical Chemistry, University of Tampere School of Medicine, Tampere 33014,
2 Finland
- 3 33. University of Lund, Dept Internal Medicine, Malmo, SE 20502, Sweden
- 4 34. University of Verona, Dept of Internal Medicine, Verona, Italy 37134
- 5 35. Uppsala University, Uppsala Clinical Research Center, SE-75185 Uppsala, Sweden
- 6 36. Department of Epidemiology, University of Groningen, University Medical Center Groningen,
7 Hanzeplein 1, 9713 GZ Groningen, The Netherlands
- 8 37. Dept of Medical Epidemiology and Biostatistics, Karolinska Institutet, Box 281, SE-171 77
9 Stockholm, Sweden
- 10 38. Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA
- 11 39. Second Department of Cardiology, Attikon Hospital, School of Medicine, University of Athens,
12 Athens, Greece
- 13 40. Children's Hospital Oakland Research Institute, Oakland, CA 94609, USA
- 14 41. Department of Cardiovascular Genetics, Institute of Cardiovascular Sciences, University College
15 London, London WC1E 6JF, UK
- 16 42. NIHR Barts Cardiovascular Biomedical Research Unit, Queen Mary University of London, London,
17 EC1M 6BQ, UK
- 18 43. Division of Endocrinology, Boston Children's Hospital, Boston, MA 02115, USA
- 19 44. Center for Basic and Translational Obesity Research, Boston Children's Hospital, Boston, MA 02115,
20 USA
- 21 45. Program in Medical and Population Genetics, Broad Institute, 7 Cambridge Center, Cambridge, MA
22 02142, USA
- 23 46. Novo Nordisk Foundation Centre for Basic Metabolic Research, Section of Metabolic, Genetics,
24 Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, 2100, Denmark
- 25 47. Department of Epidemiology Research, Statens Serum Institut, 2300, Copenhagen, Denmark
- 26 48. National Heart, Lung and Blood Institute's Framingham Heart Study, Framingham, MA 01702, USA
- 27 49. Dept. Dev. Bio. And Genetics, Stanford University Medical Center, Stanford, CA 94305, USA
- 28 50. Department of Psychiatry, VU University Medical Center, Amsterdam, The Netherlands
- 29 51. National Heart, Lung and Blood Institute, Cardiovascular Epidemiology and Human Genomics
30 Branch, Bethesda, MD 20814, USA
- 31 52. Center for Genome Science, National Institute of Health, Osong Health Technology Administration
32 Complex, Chungcheongbuk-do, Republic of Korea
- 33 53. Division of Translational Medicine and Human Genetics, Department of Medicine, University of
34 Pennsylvania, USA
- 35 54. Department of Genetics, University of North Carolina, Chapel Hill, NC 27599, USA
- 36 55. Department of Preventive Medicine and Epidemiology, Loyola University Chicago Stritch School of
37 Medicine, Maywood, IL, 60153, USA
- 38 56. Institute of Social and Preventive Medicine (IUMSP), Centre Hospitalier Universitaire Vaudois and
39 University of Lausanne, Route de la Corniche 10, 1010 Lausanne, Switzerland
- 40 57. A list of members and affiliations appears in the **Supplementary Note**
- 41 58. HudsonAlpha Institute for Biotechnology, Huntsville, AL 35086, USA
- 42 59. Department of Nutrition, University of North Carolina, Chapel Hill, NC 27599, USA
- 43 60. Genetic Epidemiology Unit, Department of Epidemiology, Erasmus MC, Rotterdam, 3015CN, The
44 Netherlands
- 45 61. Uppsala University, Department of Medical Sciences, SE-75185 Uppsala, Sweden
- 46 62. Dipartimento di Scienze Farmacologiche e Biomolecolari, Università di Milano, Milan, Italy
- 47 63. Centro Cardiologico Monzino, IRCCS, Milan, Italy

- 1 64. INSERM Centre for Research in Epidemiology and Population Health, U1018, Villejuif, France
- 2 University Paris-Sud, URMS 1018, Villejuif, France
- 3 65. Geriatric Unit, Azienda Sanitaria Firenze (ASF), Florence, Italy
- 4 66. Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, CB10 1SA, Hinxton, UK
- 5 67. University of Cambridge Metabolic Research Laboratories, Level 4, Institute of Metabolic Science
- 6 Box 289 Addenbrookes Hospital Cambridge CB2 0QQ, UK
- 7 68. NIHR Cambridge Biomedical Research Centre, Level 4, Institute of Metabolic Science Box 289
- 8 Addenbrookes Hospital Cambridge CB2 0QQ, UK
- 9 69. School of Life Science, University of Lincoln, Joseph Banks Laboratories, Lincoln LN6 7DL, UK
- 10 70. Cardiovascular Health Research Unit, Department of Medicine, University of Washington, Seattle,
- 11 WA 98101, USA
- 12 71. Human Genetics Center, School of Public Health, University of Texas Health Science Center at
- 13 Houston, 1200 Pressler St., Suite 453E, Houston, TX 77030, USA
- 14 72. Medical Genomics and Metabolic Genetics Branch, National Human Genome Research Institute,
- 15 NIH, Bethesda, MD 20892, USA
- 16 73. Department of Biological Psychology, VU University, Amsterdam, The Netherlands
- 17 74. Dept of Medicine III, University of Dresden, Medical Faculty Carl Gustav Carus, Fetscherstrasse 74,
- 18 01307 Dresden, Germany
- 19 75. The Barts Heart Centre, William Harvey Research Institute, Queen Mary University of London,
- 20 London EC1M 6BQ, UK
- 21 76. Nephrology, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Bugnon 17, 1005
- 22 Lausanne, Switzerland
- 23 77. Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London,
- 24 Norfolk Place, London W2 1PG, UK
- 25 78. Department of Cardiology, Ealing Hospital NHS Trust, Uxbridge Road, Southall, Middlesex UB1 3EU,
- 26 UK
- 27 79. Imperial College Healthcare NHS Trust, London, UK
- 28 80. National Institute of Cancer Research, National Health Research Institutes. 35 Keyan Rd., Zhunan
- 29 Town, Miaoli County 350, Taiwan
- 30 81. Singapore Eye Research Institute, Singapore National Eye Centre, Singapore 168751, Singapore
- 31 82. Duke-NUS Graduate Medical School Singapore, Singapore 169857, Singapore
- 32 83. Department of Ophthalmology, National University of Singapore and National University Health
- 33 System, Singapore 119228
- 34 84. Division of Biostatistics and Bioinformatics, Institute of Population Health Sciences, National Health
- 35 Research Institutes. 35 Keyan Rd., Zhunan Town, Miaoli County 350, Taiwan
- 36 85. University of Dundee, Ninewells Hospital and Medical School, Dundee, DD1 9SY, UK
- 37 86. Institute of Epidemiology I, Helmholtz Zentrum München, Neuherberg 85764, Germany
- 38 87. Institute of Epidemiology II, Helmholtz Zentrum München, Neuherberg 85764, Germany
- 39 88. UMR744 Inserm-Lille2-Institut Pasteur Lille, France
- 40 89. Department of Public Health and Primary Care, University of Cambridge, Cambridge CB1 8RN, UK
- 41 90. NIHR Blood and Transplant Research Unit in Donor Health and Genomics, Department of Public
- 42 Health and Primary Care, University of Cambridge, Cambridge CB1 8RN, UK
- 43 91. Division of Cardiovascular Epidemiology, Institute of Environmental Medicine, Karolinska Institutet,
- 44 Stockholm, Sweden
- 45 92. BHF Glasgow Cardiovascular Research Centre, Institute of Cardiovascular and Medical Sciences,
- 46 University of Glasgow, 126 University Place, Glasgow, G12 8QT, UK
- 47 93. Cardiovascular Epidemiology and Genetics. IMIM (Institut Hospital del Mar d'Investigacions
- 48 Mèdiques), Barcelona, Spain

- 1 94. Department of Immunology, Genetics and Pathology, University of Uppsala, Box 815, Biomedical
2 center, 751 08 Uppsala, Sweden
- 3 95. Science for Life Laboratory, University of Uppsala, Box 815, Biomedical center, 751 08 Uppsala,
4 Sweden
- 5 96. Institut für Integrative und Experimentelle Genomik, Universität zu Lübeck, Ratzeburger Allee 160,
6 23538 Lübeck, Germany
- 7 97. Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK), partner site Hamburg, Kiel, Lübeck,
8 Universität zu Lübeck, Lübeck, Germany
- 9 98. Estonian Genome Center, University of Tartu, Tartu, 51010, Estonia
- 10 99. Divisions of Endocrinology/Children's Hospital, Boston, MA 02115, USA
- 11 100. Broad Institute of Harvard and MIT, Cambridge, MA 02139 USA
- 12 101. Department of Hygiene and Epidemiology, University of Ioannina Medical School, Ioannina, 45110,
13 Greece
- 14 102. Department of Medical Sciences, Molecular Epidemiology and Science for Life Laboratory, Uppsala
15 University, Uppsala, Sweden
- 16 103. Division of Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford,
17 Oxford, OX3 9DU, UK
- 18 104. Department of Epidemiology, Erasmus MC, University Medical Center Rotterdam, P.O.Box 2040,
19 3000 CA Rotterdam, The Netherlands
- 20 105. Toulouse University School of Medicine, Rangueil University Hospital, INSERM UMR1027,
21 Toulouse, France
- 22 106. Translational Gerontology Branch, National Institute on Aging, Baltimore MD, USA
- 23 107. Institute of Molecular Medicine, University of Texas Health Science Center at Houston, TX, USA
- 24 108. Tropical Metabolism Research Unit, Tropical Medicine Research Institute, University of the West
25 Indies, Mona, Kingston 7, Jamaica
- 26 109. Department of Epidemiology, University of North Carolina, Chapel Hill, NC 27599, USA
- 27 110. Cardiothoracic Surgery Unit, Department of Molecular Medicine and Surgery, Karolinska Institutet,
28 171 76 Stockholm, Sweden
- 29 111. Institute for Population Health Sciences and Informatics, University of Edinburgh, Teviot Place,
30 Edinburgh, EH8 9AG, Scotland
- 31 112. Synpromics Ltd, 9 Bioquarter, Little France Road, Edinburgh, EH16 4UX, Scotland
- 32 113. University of Michigan Medical School, 7220 MSRB III, Ann Arbor MI 48109, USA
- 33 114. EPIMED Research Centre - Epidemiology and Preventive Medicine, Department of Clinical and
34 Experimental Medicine, University of Insubria, Varese, Italy
- 35 115. Department of Epidemiology and Prevention, IRCCS Istituto Neurologico Mediterraneo
36 NEUROMED, 86077 Pozzilli, Italy
- 37 116. Department of Cardiovascular Sciences, University of Leicester, Glenfield Hospital, Leicester LE3
38 9QP, UK
- 39 117. National Institute for Health Research Leicester Cardiovascular Biomedical Research Unit,
40 Glenfield Hospital, Leicester LE3 9QP, UK
- 41 118. Division of Endocrinology, Diabetes and Metabolism, Cedars-Sinai Medical Center, Los Angeles, CA
42 90048, USA
- 43 119. Department of Genetic Epidemiology, Institute of Epidemiology and Preventive Medicine,
44 University of Regensburg, Franz-Josef-Strauss-Allee 11, 93053 Regensburg, Germany
- 45 120. Department of Nephrology, University Hospital Regensburg, Franz-Josef-Strauss-Allee 11, 93053
46 Regensburg, Germany
- 47 121. Department of Medicine III, Division Pathobiochemistry, Technische Universität Dresden, Dresden,
48 Germany

- 1 122. Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Oxford, UK
- 2 123. Icelandic Heart Association, Kopavogur, Iceland
- 3 124. Faculty of Medicine, University of Iceland, Reykjavik, Iceland
- 4 125. Institute of Clinical Medicine/Obstetrics and Gynaecology, University of Oulu, Oulu, Finland
- 5 126. Medical Research Center, Oulu University Hospital, Oulu, Finland
- 6 127. Kuopio Research Institute of Exercise Medicine, Kuopio, Finland
- 7 128. Institute of Genetics and Molecular Medicine, Western General Hospital, Edinburgh, EH4 2XU
- 8 Scotland, UK
- 9 129. UREN, INSERM U557, INRA U1125, CNAM, SMBH, Sorbonne Paris Cité, Université Paris 13,
- 10 Bobigny, France
- 11 130. Institute of Biomedicine, University of Oulu, Medical Research Center Oulu and Oulu University
- 12 Hospital, Finland
- 13 131. Biocenter Oulu, P.O.Box 5000, Aapistie 5A, FI-90014 University of Oulu, Finland
- 14 132. Department of Gastroenterology and Metabolism, Poznan University of Medical Sciences, Poznan,
- 15 Poland
- 16 133. Center for Biomedicine, European Academy Bozen/Bolzano (EURAC), Bolzano, 39100, Italy -
- 17 affiliated institute of the University of Lübeck, Germany
- 18 134. Department of Genetics, Harvard Medical School, Boston, 02115, USA
- 19 135. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA
- 20 136. HUNT Research Centre, Department of Public Health and General Practice, Norwegian University
- 21 of Science and Technology, 7600 Levanger, Norway
- 22 137. St. Olav Hospital, Trondheim University Hospital, Trondheim, Norway
- 23 138. Cardiovascular Genetics Division, University of Utah School of Medicine, Salt Lake City, Utah, USA
- 24 139. Department of Genetic Medicine, Weill Cornell Medical College Qatar, Doha, Qatar
- 25 140. Department of Radiology, Erasmus MC, The Netherlands
- 26 141. Department of Neurology, Erasmus MC, University Medical Center Rotterdam, P.O.Box 2040, 3000
- 27 CA Rotterdam, The Netherlands
- 28 142. Research Unit of Molecular Epidemiology, Helmholtz Zentrum München, Neuherberg 85764,
- 29 Germany
- 30 143. Hannover Unified Biobank, Hannover Medical School, Hannover 30625, Germany
- 31 144. Hannover Medical School, Institute for Human Genetics, Carl-Neuberg-Strasse 1, 30625 Hanover,
- 32 Germany
- 33 145. Kaiser Permanente, Division of Research, Oakland, CA 94612, USA
- 34 146. Department of Medicine, University of Washington, Seattle, Washington 98101, USA
- 35 147. Department of Clinical Physiology, Tampere University Hospital, Tampere 33521, Finland
- 36 148. Center for Human Genetic Research, Massachusetts General Hospital, Boston, MA 02114, USA
- 37 149. Cardiovascular Research Center, Massachusetts General Hospital, Boston, MA 02114, USA
- 38 150. Department of Medicine, Harvard Medical School, Boston, MA, USA
- 39 151. Cardiology Division, Department of Medicine, Massachusetts General Hospital
- 40 152. Division of Transplantation, Department of Surgery, University of Pennsylvania, PA 19104 USA
- 41 153. Department of Pediatrics, University of Pennsylvania, Philadelphia, PA, USA
- 42 154. Department of Public Health and Primary Care, Institute of Public Health, University of Cambridge,
- 43 Cambridge CB2 2SR, UK
- 44 155. Institute for Translational Genomics and Population Sciences, Department of Pediatrics, LABioMed
- 45 at Harbor-UCLA Medical Center, 1124 W. Carson Street, Torrance, CA 90502, USA
- 46 156. 1st Cardiology Department, Onassis Cardiac Surgery Center 356, Sygrou Ave, Athens, Greece
- 47 157. National Heart and Lung Institute, Imperial College London, Hammersmith Hospital Campus,
- 48 Ducane Road, London W12 0NN, UK

- 1 158. Department of Medicine, Children's Hospital Oakland Research Institute, Oakland, CA 94609, USA
- 2 159. MRC Unit for Lifelong Health and Ageing at UCL, London, WC1B 5JU, UK
- 3 160. Department of Medical Genetics, University of Lausanne, Lausanne, Switzerland
- 4 161. Swiss Institute of Bioinformatics, Lausanne, Switzerland
- 5 162. Department of Medicine, University of Eastern Finland and Kuopio University Hospital, 70210
- 6 Kuopio, Finland
- 7 163. Institute of Biomedicine/Physiology, University of Eastern Finland, Kuopio Campus, Finland
- 8 164. Department of Clinical Physiology and Nuclear Medicine, Kuopio University Hospital, Kuopio,
- 9 Finland
- 10 165. Office of Population Studies Foundation Inc., Talamban, Cebu City, 6000, Philippines
- 11 166. Department of Anthropology, Sociology, and History, University of San Carlos, Talamban, Cebu
- 12 City, 6000, Philippines
- 13 167. Division of Endocrine and Metabolism, Department of Internal Medicine, Chichung Veterans
- 14 General Hospital, Taichung 40705, Taiwan
- 15 168. School of Medicine, National Yang-Ming University, Taipei, Taiwan
- 16 169. Department of Medical Research, Taichung Veterans General Hospital, Taichung 407, Taiwan
- 17 170. Population Sciences Branch, National Heart Lung, and Blood Institute, National Institutes of
- 18 Health, Bethesda, MD, USA
- 19 171. Cardiovascular Center, Taichung Veterans General Hospital, Taichung, 40705, Taiwan
- 20 172. Institute of Clinical Medicine, National Yang Ming University School of Medicine, Taipei 112,
- 21 Taiwan
- 22 173. Section of Computational Biomedicine, Department of Medicine, Boston University School of
- 23 Medicine, Boston, 02446 MA, USA
- 24 174. European Genomic Institute for Diabetes (EGID), FR 3508 Lille, France
- 25 175. Centre National de la Recherche Scientifique (CNRS) UMR 8199, Lille Pasteur Institute, 1 rue du
- 26 Prof Calmette, 59019 Lille Cedex, France
- 27 176. Lille 2 University, Lille, France
- 28 177. Center for Evidence-based Healthcare, University of Dresden, Medical Faculty Carl Gustav Carus,
- 29 Fetscherstrasse 74, 01307 Dresden, Germany
- 30 178. Department of Medicine I, University Hospital Grosshadern, Ludwig-Maximilians University,
- 31 Munich, Germany
- 32 179. Institute of Medical Informatics, Biometry and Epidemiology, Chair of Epidemiology, Ludwig-
- 33 Maximilians-Universität, München 81377, Germany
- 34 180. Neurology Unit, University of Cambridge, R3, Box 83, Cambridge Biomedical Campus, Cambridge,
- 35 Cb2 0QQ, UK
- 36 181. Department of Dietetics-Nutrition, Harokopio University, 70 El. Venizelou Str, Athens, Greece
- 37 182. INSERM U1142 LIMICS, UMR_S 1142 Sorbonne Universités, UPMC Université Paris 06, Université
- 38 Paris 13, Paris, France
- 39 183. Department of Twin Research and Genetic Epidemiology, King's College London, London, UK
- 40 184. Department of Life and Reproduction Sciences, University of Verona, Strada le Grazie 8, 37134
- 41 Verona, Italy
- 42 185. Department of Medicine, Kuopio University Hospital, Kuopio, Finland
- 43 186. Unit of General Practice, Oulu University Hospital, Oulu, Finland
- 44 187. Department of Medicine, Program for Personalized and Genomic Medicine, University of
- 45 Maryland, School of Medicine, Baltimore, Maryland 21201, USA
- 46 188. Department of Epidemiology, Human Genetics and Environmental Sciences, School of Public
- 47 Health, University of Texas Health Science Center at Houston, 1200 Pressler St., Suite 453E, Houston, TX
- 48 77030, USA

- 1 189. Istituto di Ricerca Genetica e Biomedica (IRGB), Consiglio Nazionale delle Ricerche, c/o Cittadella
- 2 Universitaria di Monseratto, Monserrato, Cagliari 09042, Italy
- 3 190. Department of Cardiology, School of Medicine, University of Tampere, Tampere 33014, Finland
- 4 191. School of Medicine, University of Tampere, Tampere 33014, Finland
- 5 192. National Heart, Lung and Blood Institute, Division of Intramural Research, Bethesda, MD, USA
- 6 193. Institute of Psychiatry, Psychology and Neuroscience, King's College London, London SE5 8AF, UK
- 7 194. Divisions of Endocrinology, Children's Hospital Boston, Massachusetts 02115, USA
- 8 195. Genetics and Program in Genomics, Children's Hospital Boston, Massachusetts 02115, USA
- 9 196. Department of Psychiatry, EMGO Institute, Neuroscience Campus, VU University Medical Centre,
- 10 Van der Boechorststraat 7, 1081 BT Amsterdam, The Netherlands
- 11 197. Department of Psychiatry, University of Groningen, University Medical Center Groningen,
- 12 Hanzeplein 1, 9713 GZ Groningen, The Netherlands
- 13 198. Department of Psychiatry, Leiden University Medical Centre, P.O. Box 9600, 2300 RC Leiden, The
- 14 Netherlands
- 15 199. International Centre for Circulatory Health, Imperial College London, W2 1PG, UK
- 16 200. Department of Neurology, General Central Hospital, Bolzano, 39100, Italy
- 17 201. Department of Neurology, University of Lübeck, Lübeck, Germany
- 18 202. Department of Epidemiology, University of Washington, Seattle, WA, USA
- 19 203. Department of Health Services, University of Washington, Seattle, WA
- 20 204. Group Health Research Institute, Group Health Cooperative, Seattle, WA
- 21 205. Division of Biostatistics, Washington University School of Medicine, Saint Louis, MO, 63110, USA
- 22 206. Center for Non-Communicable Diseases, Karachi, Pakistan
- 23 207. Department of Nutrition, Harvard School of Public Health, Boston, MA, USA
- 24 208. Institute of Physiology, University Medicine Greifswald, Greifswald, Germany
- 25 209. Department of Biostatistics, University of Washington, Seattle, WA, USA
- 26 210. University of Ottawa Heart Institute, Cardiovascular Research Methods Centre Ontario, Canada
- 27 211. Ruddy Canadian Cardiovascular Genetics Centre, Ontario, Canada
- 28 212. National Heart, Lung, and Blood Institute, 6701 Rockledge Ave., Bethesda, MD 20892, USA
- 29 213. Leicester NIHR Biomedical Research Unit in Cardiovascular Disease, Glenfield Hospital, Leicester
- 30 LE3 9QP, UK
- 31 214. South Karelia Central Hospital, Lappeenranta, Finland
- 32 215. Deutsches Herzzentrum München, Germany
- 33 216. Technische Universität München, Germany
- 34 217. Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK), München, Germany
- 35 218. Munich Heart Alliance, Germany
- 36 219. Center For Life-course Health Research, P.O.Box 5000, FI-90014 University of Oulu, Finland
- 37 220. College of Medicine, National Defense Medical Center, Taipei, Taiwan
- 38 221. Saw Swee Hock School of Public Health, National University of Singapore and National University
- 39 Health System, Singapore 117597
- 40 222. University of Eastern Finland and Kuopio University Hospital, 70210 Kuopio, Finland
- 41 223. Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Dublin 4,
- 42 Ireland
- 43 224. Department of Haematology, University of Cambridge, Cambridge, UK
- 44 225. Department of Medicine, National University of Singapore and National University Health System,
- 45 Singapore 119228, Singapore
- 46 226. Laboratory of Cardiovascular Science, Intramural Research Program, National Institute on Aging,
- 47 National Institutes of Health, Baltimore, Maryland, 21224, USA
- 48 227. Institute for Community Medicine, University Medicine Greifswald, Greifswald, Germany

- 1 228. Department of Health Sciences, University of Leicester, University Rd, Leicester LE1 7RH, UK
- 2 229. Department of internal medicine, Erasmus MC, Rotterdam, 3000CA, The Netherlands
- 3 230. Department of Public Health and Clinical Nutrition, University of Eastern Finland, Finland
- 4 231. Research Unit, Kuopio University Hospital, Kuopio, Finland
- 5 232. Research Institute for Primordial Prevention of Non-communicable Disease, Isfahan University of
- 6 Medical Sciences, Isfahan, Iran
- 7 233. Johns Hopkins Medical Institutions, 1830 East Monument St., Baltimore, MD 21287, USA
- 8 234. Centre of Medical Systems Biology (CMSB 1-2), NCI Erasmus Medical Center, Rotterdam, The
- 9 Netherlands
- 10 235. Department of Clinical Epidemiology, Biostatistics and Bioinformatics, Academic Medical Center,
- 11 Amsterdam, The Netherlands
- 12 236. Durrer Center for Cardiogenetic Research, ICIN-Netherlands Heart Institute, Utrecht, The
- 13 Netherlands
- 14 237. Section of Preventive medicine, Department of Medicine, Boston University School of Medicine,
- 15 Boston, 02446 MA, USA
- 16 238. Cardiology, Department of Medicine, Boston University School of Medicine, Boston, 02446 MA,
- 17 USA
- 18 239. Department of Pharmacology, University of Pennsylvania Perelman School of Medicine,
- 19 Philadelphia, Pennsylvania, USA
- 20 240. Department of Internal medicine, University Hospital Lausanne, Lausanne, Switzerland
- 21 241. Department of Epidemiology and Public Health, EA3430, University of Strasbourg, Strasbourg,
- 22 France
- 23 242. Division of Cardiovascular Medicine, Department of Internal Medicine, University of Michigan
- 24 Medical School, Ann Arbor, MI, USA
- 25 243. University Medical Center Groningen, University of Groningen, Groningen, 9700RB, The
- 26 Netherlands
- 27 244. Epidemiology Research Unit, Tropical Medicine Research Institute, University of the West Indies,
- 28 Mona, Kingston 7, Jamaica
- 29 245. Department of Community Medicine, Faculty of Health Sciences, University of Tromsø, Tromsø,
- 30 Norway
- 31 246. Department of Clinical Medicine, Faculty of Health Sciences, University of Tromsø, Tromsø, Norway
- 32 247. MRC Cancer Unit, University of Cambridge, Cambridge, UK
- 33 248. Department of Epidemiology and Biostatistics, School of Medicine, Case Western Reserve
- 34 University, Cleveland, OH, 44106, USA
- 35 249. Ministry of Health, Victoria, Republic of Seychelles
- 36 250. Department of Biostatistics and Epidemiology, University of Pennsylvania, USA
- 37 251. MRC-PHE Centre for Environment and Health, School of Public Health, Imperial College London,
- 38 Norfolk Place, London W2 1PG, UK
- 39 252. Enterprise Informatics, Illumina Inc., Santa Clara CA, 95050, USA
- 40 253. Department of Internal Medicine, Division of Cardiovascular Medicine, University of Michigan, Ann
- 41 Arbor, MI 48109, USA
- 42 254. Department of Human Genetics, University of Michigan, Ann Arbor, Michigan, USA
- 43 255. Department of Genetics, University of Groningen, University Medical Centre Groningen,
- 44 Groningen, 9711, The Netherlands
- 45 256. Dept Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands
- 46 257. Department of Medicine, Central Finland Health Care District, Jyväskylä, Finland
- 47 258. Dasman Diabetes Institute, Dasman, 15462 Kuwait
- 48 259. Saudi Diabetes Research Group, King Abdulaziz University, 21589 Jeddah, Saudi Arabia

- 1 260. Centre for Vascular Prevention, Danube-University Krems, 3500 Krems, Austria
- 2 261. Department of Medicine, Columbia University, 622 West 168th St., New York, NY 10032, USA
- 3 262. Synlab Academy, Synlab Services GmbH, P5, 7, 68161 Mannheim, Germany
- 4 263. Clinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University of Graz, 8036
- 5 Graz, Austria
- 6 264. Unit of Primary Care, Oulu University Hospital, Kajaanintie 50, P.O.Box 20, FI-90220 Oulu, 90029
- 7 OYS, Finland
- 8 265. Grosshadern, Klinikum, München 81377, Germany
- 9 266. The Charles Bronfman Institute for Personalized Medicine, The Icahn School of Medicine at Mount
- 10 Sinai, New York, NY 10029, USA
- 11 267. Mindich Child health Development Institute, The Icahn School of Medicine at Mount Sinai, New
- 12 York, NY 10029, USA
- 13 268. Princess Al-Jawhara Al-Brahim Centre of Excellence in Research of Hereditary Disorders (PACER-
- 14 HD), King Abdulaziz University, Jeddah 21589, Saudi Arabia
- 15 269. Department of Biostatistics, University of Liverpool, Liverpool L69 3GA, UK
- 16

1 **ABSTRACT**

2 To dissect the genetic architecture of blood pressure and assess effects on target-organ damage,
3 we analyzed 128,272 SNPs from targeted and genome-wide arrays in 201,529 individuals of European
4 ancestry and genotypes from an additional 140,886 individuals were used for validation. We identified
5 66 blood pressure loci, of which 17 were novel and 15 harbored multiple distinct association signals.
6 The 66 index SNPs were enriched for *cis*-regulatory elements, particularly in vascular endothelial cells,
7 consistent with a primary role in blood pressure control through modulation of vascular tone across
8 multiple tissues. The 66 index SNPs combined in a risk score showed comparable effects in 64,421
9 individuals of non-European descent. The 66-SNP blood pressure risk score was significantly associated
10 with target-organ damage in multiple tissues, with minor effects in the kidney. Our findings expand
11 current knowledge of blood pressure pathways and highlight tissues beyond the classic renal system in
12 blood pressure regulation.

1 INTRODUCTION

2 There are considerable physiological, clinical and genetic data that point to the kidney as the
3 major regulator of blood pressure (BP) and to renal damage as a consequence of long-term BP elevation.
4 However, alternative hypotheses, such as increasing systemic vascular resistance, are also serious
5 contenders to explain the rise of BP with increasing age, but with limited genetic support. The genetic
6 basis of elevated blood pressure or hypertension (HTN) involves many loci that have been identified
7 using large-scale analyses of candidate genes^{1,2}, linkage studies, and genome-wide association studies
8 (GWAS)³⁻¹². The genes underlying BP regulation can help resolve many of the open questions regarding
9 BP (patho-) physiology. While ~40-50% of BP variability is heritable^{13,14}, the genetic variation identified
10 to date explains only ~2%¹⁻¹².

11 The Cardio-MetaboChip is a custom genotyping microarray designed to facilitate cost-effective
12 follow-up of nominal associations for metabolic and cardiovascular traits, including BP. This array
13 comprises 196,725 variants, including ~5,000 SNPs with nominal ($P < 0.016$) evidence of BP association in
14 our previous GWAS meta-analysis⁵. Furthermore, the array includes several dense scaffolds for fine
15 mapping of selected loci spanning, on average, genomic regions of 350 kilobases^{5,16}, of which 24 include
16 genome-wide significant BP association in the current study^{5,16}.

17 RESULTS

18 Novel genetic loci associated with systolic and diastolic BP

19 We performed meta-analyses of association summary statistics from a total of 201,529
20 individuals of European (EUR) ancestry from 74 studies: (i) 109,096 individuals from 46 studies
21 genotyped on Cardio-MetaboChip; and (ii) 92,433 individuals from 28 studies with imputed genotype
22 data from genome-wide genotyping at variants included on the Cardio-MetaboChip. Twenty-four of the
23 28 studies with genome-wide genotyping data had contributed to previous analyses (**Supplementary**
24 **Tables 1-3**)^{5,7}.

25 BP was measured using standardized protocols in all studies^{5,17} (**Supplementary Table 1, Online**
26 **methods**). Association statistics for systolic and diastolic BP (SBP and DBP) in models adjusting for age,
27 age², sex, and body mass index (BMI), were obtained for each study separately, with study-specific
28 genomic control applied to correct for possible population structure. Fixed-effects meta-analysis
29 proceeded in 4 stages, separately for the following SNP associations: Stage 1, using results based on 46
30 studies using Cardio-MetaboChip genotypes of 109,096 participants; Stage 2, using additional results
31 based on imputed genotypes from genome-wide genotyping arrays in 4 previously unpublished studies;

1 Stage 3 using imputed genotypes from genome-wide genotyping arrays in 24 previously published
2 studies⁵; and Stage 4, the joint meta-analysis of Stages 1-3 including a total of 201,529 independent
3 individuals (**Supplementary Figure 1, Supplementary Tables 2-3, Supplementary Note**). To account for
4 population structure between studies in Stages 1-3 of our meta-analysis, genomic control correction was
5 applied to meta-analysis results from each of these stages in an approach aggregating summary
6 statistics from GWAS and Cardio-MetaboChip studies^{18,19}.

7 After stage 4, 67 loci attained genome-wide significance ($P < 5 \times 10^{-8}$), 18 of which were not
8 previously reported in the literature (**Supplementary Table 4**). Quantile-quantile plots of the stage 4
9 meta-analysis showed an excess of small P values, with an elevated genomic control lambda estimate
10 that was persistent, albeit attenuated, after excluding all 66 loci (**Supplementary Figure 2**). This
11 observation is compatible with either residual uncorrected population stratification or the presence of a
12 large number of variants that are truly associated with BP but fail to achieve genome-wide significance
13 in the current meta-analysis. The Cardio-MetaboChip array's inclusion of SNPs from a prior BP GWAS⁵
14 does not appear to be the sole explanation, as we did not observe a significant decrease of the excess of
15 small P values after exclusion of all SNPs that were included on the Cardio-MetaboChip based on
16 nominal BP association (**Supplementary Figures 3 and 4**). Since the quantile-quantile plots continued to
17 show deviation from the null expectation, we sought additional validation for 18 variants attaining
18 genome-wide significance, but without prior support in the literature, in up to 140,886 individuals of
19 European ancestry from UK Biobank²⁰. For these SNPs, we performed a stage 5 meta-analysis combining
20 the association summary statistics from stage 4 and UK Biobank, in a total of up to 342,415 individuals
21 (**Supplementary Table 5**).

22 Upon stage 5 meta-analysis, 17 of 18 variants retained genome-wide significance for the primary
23 trait (SBP or DBP result with the lower P value). The one variant that was not genome-wide significant
24 had a borderline P value of 4.49×10^{-8} at stage 4. These findings are consistent with appropriate
25 calibration of the association test statistics at stage 4 such that observing one failure among 18
26 validation tests is consistent with the use of a threshold ($P < 5 \times 10^{-8}$) designed to have a 1 in 20 chance
27 of a result as or more extreme solely due to chance. In total, 66 loci attained genome-wide significance:
28 13 loci for SBP only, 12 loci for DBP only, and 41 loci for both traits. Of these, 17 BP loci were novel,
29 while 49 were previously reported at genome-wide significance (**Table 1 and Figure 1**).

30 Compared with previously reported BP variants^{5,7,21}, the average absolute effect size of the
31 newly discovered variants is smaller, with comparable minor allele frequency (MAF), presumably owing
32 to the increased power of a larger sample size (**Table 2**). As expected from the high correlation between

1 SBP and DBP effects, the observed directions of effects for the two traits were generally concordant
2 (**Supplementary Figure 5**), and the absolute effect sizes were inversely correlated with MAF (**Table 1**
3 and **Supplementary Figure 6**). The 66 BP SNPs explained 3.46% and 3.36% of SBP and DBP variance,
4 respectively, a modest increase from 2.95% and 2.78% for SBP and DBP, respectively, for the 49
5 previously reported SNPs (**Supplementary Note**). The low percent variance explained is consistent with
6 estimates that large numbers of common variants with weak effects at a large number of loci influence
7 BP⁵.

8 **Signal refinement at the 66 BP loci**

9 To identify distinct signals of association at the 66 BP loci and the variants most likely to be
10 causal for each, we started with an approximate conditional analysis using a model selection procedure
11 implemented in the GCTA-COJO package^{22,23} as well as a detailed literature review of all published BP
12 association studies. GCTA-COJO analysis was performed using the association summary statistics for SBP
13 and DBP from the Stage 4 EUR ancestry meta-analyses, with the linkage disequilibrium (LD) between
14 variants estimated on the basis of Cardio-MetaboChip genotype data from 7,006 individuals of EUR
15 ancestry from the GoDARTS cohort²⁴. More than one distinct BP association signal was identified at 13
16 loci at $P < 5 \times 10^{-8}$ (**Supplementary Table 6, Supplementary Figures 7, and Supplementary Note**). At six
17 loci, the distinct signals were identified for both SBP and DBP analyzed separately; these trait-specific
18 associations were represented by the same or highly correlated ($r^2 > 0.8$) SNPs at 5 of the 6 loci
19 (**Supplementary Tables 7 and 8**). We repeated GCTA-COJO analyses using the same summary
20 association results, but with a different reference sample for LD estimates (WTCCC1-T2D/58BC, N =
21 2,947, **Supplementary Note**) and observed minimal differences arising from minor fluctuations in the
22 association P value in the joint regression models (**Supplementary Tables 7 and 8**). LD-based
23 comparisons of published association signals at established BP loci, and the current study's findings
24 suggested that at 10 loci, the signals identified by the single-SNP and the GCTA-COJO analyses were
25 distinct from those reported in the literature (**Supplementary Table 9**).

26 We then performed multivariable regression modeling in a single large cohort (Women's
27 Genome Health Study, WGHS, N = 23,047) with simultaneous adjustment for both 1) all combinations of
28 putative index SNPs for each distinct signal from the GCTA-COJO conditional analyses, and 2) all index
29 SNPs for all potential distinct signals identified by our literature review (**Supplementary Table 9,**
30 **Supplementary Note**). Although WGHS is very large as a single study, power is reduced in a single
31 sample compared to that in the overall meta-analysis (23k vs. 342k individuals) and consequently the

1 failure to reach significance does not represent non-replication for individual SNPs. The WGHS analysis
2 supported two distinct association signals at eight of 13 loci identified in the GCTA-COJO analysis, but
3 could not provide support for the remaining five (**Supplementary Table 10**). The joint SNP modeling in
4 WGHS additionally supported two distinct signals of association at three other loci (*GUCY1A3-GUCY1B3*,
5 *SYNPO2L* and *TBX5-TBX3*), at which the SNP identified in the current study is distinct from that
6 previously reported in the literature^{5,11}.

7 We sought to refine the localization of likely functional variants at loci with high-density
8 coverage on the Cardio-MetaboChip. We followed a Bayesian approach to define, for each signal,
9 credible sets of variants that have 99% probability of containing or tagging the causal variant
10 (**Supplementary Note**). To improve the resolution of the method, the analyses were restricted to 24
11 regions selected to fine map (FM) genetic associations, and that included at least one SNP reaching
12 genome-wide significance in the current meta-analyses (**Supplementary Table 11**). Twenty-one of the
13 Cardio-MetaboChip FM regions were BP loci in the original design, with three of the newly discovered
14 BP loci in FM regions that were originally selected for other non-BP traits. We observed that the 99%
15 credible SNP sets at five BP loci spanned <20kb. The greatest refinement was observed at the *SLC39A8*
16 locus for SBP and DBP, and at the *ZC3HC1* and *PLCE1* loci for DBP, where the 99% credible sets included
17 only the index variants (**Supplementary Table 12**). Although SNPs in credible sets were primarily non-
18 coding, they included one synonymous and seven non-synonymous variants that attained high posterior
19 probability of driving seven distinct association signals at six BP loci (**Supplementary Table 12**). Of
20 these, three variants alone account for more than 95% of the posterior probability of driving the
21 association signal observed at each of three loci (**Supplementary Table 12 and 13**). Despite reduced
22 statistical power, the analyses restricted to the samples with Cardio-MetaboChip genotypes only
23 (N = 109,096) identified the majority of SNPs identified in the GWAS+Cardio-MetaboChip data
24 (**Supplementary Table 12**). The full list of SNPs in the 99% credible sets are listed in **Supplementary**
25 **Table 13**.

26 **What do the BP variants do?**

27 Index SNPs or their proxies ($r^2 > 0.8$) altered amino acid sequence at 11 of 66 BP loci (**Table 1**).
28 Thus, the majority of BP-association signals are likely driven by non-coding variants hypothesized to
29 regulate expression of some nearby gene in *cis*. To characterize their effects, we first sought SNPs
30 associated with gene expression (eSNPs) from a range of available expression data which included
31 hypertension target end organs and cells of the circulatory system (heart tissue, kidney tissue, brain

1 tissue, aortic endothelial cells, blood vessels) and other tissue/cell types (CD4⁺ macrophages, monocytes
2 lymphoblastoid cell lines, skin tissue, fat tissue, and liver tissue). Fourteen BP-associated SNPs at the
3 *MTHFR-NPPB*, *MDM4*, *ULK4*, *CYP1A1-ULK3*, *ADM*, *FURIN-FES*, *FIGN*, and *PSMD5* loci were eSNPs across
4 different tissues (**Supplementary Table 14**). Of these 14 eSNPs, three were also predicted to alter the
5 amino acid sequence at the *MTHFR-NPPB*, *MAP4* and *ULK4* loci, providing two potential mechanisms to
6 explore in functional studies. Second, we used gene expression levels measured in whole blood in two
7 different samples each including >5,000 individuals of EUR descent. We tested whether the lead BP SNP
8 was associated with expression of any transcript in *cis* (<1Mb from the lead SNP at each locus) at a false
9 discovery rate (FDR) of < 0.05, accounting for all possible *cis*-transcript association tests genome-wide.
10 It is likely that we did not genotype the causal genetic variant underlying each BP association signal; a
11 nearby SNP-transcript association, due to LD, may therefore reflect an independent genetic effect on
12 expression that is unrelated to the BP effect. Consequently, we assumed that the lead BP SNP and the
13 most significant eSNP for a given transcript should be highly correlated ($r^2 > 0.7$). Furthermore, we
14 assumed that the significance of the transcript association with the lead BP SNP should be substantially
15 reduced in a conditional model adjusting for the best eSNP for a given transcript. Eighteen SNPs at 15
16 loci were associated with 22 different transcripts, with a total of 23 independent SNP-transcript
17 associations (three SNPs were associated with two transcripts each, **Supplementary Table 15**,
18 **Supplementary Note**). The genes expressed in a BP SNP allele-specific manner are clearly high-priority
19 candidates to mediate the BP association. In whole blood, these genes included obvious biological
20 candidates such as *GUCY1A3*, encoding the alpha subunit of the soluble guanylate cyclase protein, and
21 *ADM*, encoding adrenomedullin, both of which are known to induce vasodilation^{25,26}. There was some
22 overlap of eSNPs between the whole blood and other tissue datasets at the *MTHFR-NPPB*, *MDM4*,
23 *PSMD5*, *ULK4* and *CYP1A1-ULK3* loci, illustrating additional potentially causal genes for further study.

24 An alternative method for understanding the effect on BP of non-coding variants is to determine
25 whether they fall within DNaseI hypersensitivity sites (DHSs). We performed two analyses to investigate
26 whether BP SNPs or their LD proxies ($r^2 > 0.8$) were enriched in DHSs in a cell-type-specific manner
27 (**Supplementary Note**). First, we used Epigenomics Roadmap and ENCODE DHS data from 123 adult cell
28 lines or tissues²⁷⁻²⁹ to estimate the fold increase in the proportion of BP SNPs mapping to DHSs
29 compared to SNPs associated at genome-wide significance with non-BP phenotypes from the NHGRI
30 GWAS catalog³⁰. We observed that 7 out of the 10 cell types with the greatest relative enrichment of BP
31 SNPs mapping to DHSs were from blood vessels (vascular or micro-vascular endothelial cell-lines or cells)
32 and 11 of the 12 endothelial cells were among the top quarter most enriched among the 123 cell types

1 **(Figure 2 and Supplementary Table 16)**. In a second analysis of an expanded set of tissues and cell lines,
2 in which cell types were grouped into tissues (**Supplementary Table 17**), BP-associated SNP enrichment
3 in DHSs in blood vessels was again observed ($P = 1.2 \times 10^{-9}$), as well as in heart samples ($P = 5.3 \times 10^{-8}$;
4 **Supplementary Table 18**).

5 We next tested whether there was enrichment of BP SNPs in H3K4me3³¹ sites, a methylation
6 mark associated with both promoter and enhancer DNA. We observed significant enrichment in a range
7 of cell types including CD34 primary cells, adult kidney cells, and muscle satellite cultured cells
8 (**Supplementary Table 19**). Enrichment of BP SNPs in predicted strong and weak enhancer states and in
9 active promoters³² in a range of cell types was also observed (**Supplementary Table 20, Supplementary**
10 **Figure 8**).

11 We used Meta-Analysis Gene-set Enrichment of variant Associations (MAGENTA)³³ to attempt
12 to identify pathways over-represented in the BP association results. No gene sets meeting experiment-
13 wide significance for enrichment for BP association were identified by MAGENTA after correction for
14 multiple testing, although some attained nominal significance (**Supplementary Table 21, Supplementary**
15 **Note**). We also adapted the DEPICT³⁴ pathway analysis tool (Data-driven Expression Prioritized
16 Integration for Complex Traits) to identify assembled gene-sets that are enriched for genes near
17 associated variants, and to assess whether genes from associated loci were highly expressed in
18 particular tissues or cell types. Using the extended BP locus list based on genome-wide significant loci
19 from this analysis and previously published SNPs that may not have reached genome-wide significance
20 in the current analysis (**Supplementary Table 9**), we identified five significant ($FDR \leq 5\%$) gene sets:
21 abnormal cardiovascular system physiology, G Alpha 1213 signaling events, embryonic growth
22 retardation, prolonged QT interval, and abnormal vitelline vasculature morphology. We also found that
23 suggestive SBP and DBP associations ($P < 1 \times 10^{-5}$) were enriched for reconstituted gene-sets at DBP loci
24 (mainly related to developmental pathways), but not at SBP loci (**Supplementary Table 22,**
25 **Supplementary Note**). In a final analysis, we assessed Cardio-MetaboChip SNPs at the fine-mapping loci
26 using formaldehyde-assisted isolation of regulatory elements (FAIRE-gen) in lymphoblastoid cell lines³⁵.
27 Our results provided support for two SNPs, one of which SNP (rs7961796 at the *TBX5-TBX3* locus) was
28 located in a regulatory site. Although the other SNP (rs3184504 at the *SH2B3* locus) is a non-
29 synonymous variant, there was also a regulatory site indicated by DNaseI and H3K4me1 signatures at
30 the locus, making the SNP a potential regulatory variant (**Supplementary Table 23**)³⁶. Both SNPs were
31 included in the list of 99% credible SNPs at each locus.

1 Asian- and African ancestry BP SNP association

2 We tested the 66 lead SNPs at the established and novel loci for association with BP in up to
3 20,875 individuals of South Asian (SAS) ancestry (PROMIS and RACE studies), 9,637 individuals of East
4 Asian (EAS) ancestry (HEXA, HALST, CLHNS, DRAGON, and TUDR studies), and 33,909 individuals of
5 African (AFR) ancestry (COGENT-BP consortium, Jupiter, SPT, Seychelles, GXE, and TANDEM studies). As
6 expected, the effect allele frequencies are very similar across studies of the same ethnicity, but
7 markedly different across different ancestry groups (**Supplementary Figure 9**). Many associations of
8 individual SNPs failed to reach $P < 0.05$ for the BP trait with the lower P value (**Supplementary Table 24**),
9 which could potentially be due to the much lower statistical power at the sample sizes available,
10 different patterns of LD at each locus across ancestries, variability in allele frequency, or true lack of
11 association in individuals of a given non-European ancestry. The low statistical power for the great
12 majority of SNPs tested is visible considering SNP-by-SNP power calculations using European ancestry
13 effect sizes (**Supplementary Table 24**). However, concordant directions of allelic effects for both SBP
14 and DBP were observed for 45/66 SNPs in SAS, 36/60 SNPs in EAS, and 42/66 SNPs in AFR samples: the
15 strongest concordance with SAS may not be surprising because South Asians are more closely related to
16 Europeans than are East Asians or Africans. Moreover, strong correlation of effect sizes was observed
17 between EUR samples with SAS, EAS, or AFR samples ($r = 0.55, 0.60,$ and $0.48,$ respectively). A 66-SNP
18 SBP or DBP risk score were significant predictors of SBP and DBP in all samples. A 1 mm Hg higher SBP or
19 DBP risk score in EUR samples was associated with a 0.58/0.50 mm Hg higher SBP/DBP in SAS samples
20 (SBP $P = 1.5 \times 10^{-19}$, DBP $P = 3.2 \times 10^{-15}$), 0.49/0.50 mm Hg higher SBP/DBP in EAS samples (SBP
21 $P = 1.9 \times 10^{-10}$, DBP $P = 1.3 \times 10^{-7}$), and 0.51/0.47 mm Hg higher SBP/DBP in AFR samples (SBP
22 $P = 2.2 \times 10^{-21}$, DBP $P = 6.5 \times 10^{-19}$). The attenuation of the genetic risk score estimates in non-European
23 ancestries is presumably due to inclusion of a subset of variants that lack association in the non-
24 European or admixed samples.

25 We subsequently performed a trans-ethnic meta-analysis of the 66 SNPs in all 64,421 samples
26 across the three non-European ancestries. After correcting for 66 tests, 12/66 SNPs were significantly
27 associated with either SBP or DBP ($P < 7.6 \times 10^{-4}$), with a correlation of EUR and non-EUR effect
28 estimates of 0.77 for SBP and 0.67 for DBP; the European-ancestry SBP or DBP risk score was associated
29 with 0.53/0.48 mm Hg higher BP per predicted mm Hg SBP/DBP respectively (SBP $P < 6.6 \times 10^{-48}$, DBP
30 $P < 1.3 \times 10^{-38}$). For 7 of the 12 significant SNPs, no association has previously been reported in genome-
31 wide studies of non-European ancestry. Some heterogeneity of effects was observed between
32 European and non-European effect estimates (**Supplementary Table 24**). Taken together, these findings

1 suggest that, in aggregate, BP loci identified using data from individuals of EUR ancestry are also
2 predictive of BP in non-EUR samples, but larger non-European sample sizes will be needed to establish
3 precisely which individual SNPs are associated in a given ethnic group.

4 **Impact on hypertensive target organ damage**

5 Long-term elevated BP causes target organ damage, especially in the heart, kidney, brain, large
6 blood vessels, and the retinal vessels³⁷. Consequently, the genetic effect of the 66 SBP and DBP SNPs on
7 end-organ outcomes can be directly tested using the risk score, although some outcomes lacked results
8 for a small number of SNPs. Interestingly, BP risk scores significantly predicted (**Supplementary Note**)
9 coronary artery disease risk, left ventricular mass and wall thickness, stroke, urinary albumin/creatinine
10 ratio, carotid intima-medial thickness and central retinal artery caliber, but not heart failure or other
11 kidney phenotypes, after accounting for the number of outcomes examined (**Table 3**). Because outlier
12 effects can affect risk scores, we repeated the risk score analysis removing iteratively SNPs that
13 contributed to statistical heterogeneity (SNP-trait effects relative to SNP-BP effects). Heterogeneity was
14 defined based on a multiple testing adjusted significance threshold for Cochran's Q test of homogeneity
15 of effects (**Supplementary Note**). The risk score analyses restricted to the subset of SNPs showing no
16 heterogeneity of effect revealed essentially identical results, with the exception that urinary
17 albumin/creatinine ratio was no longer significant. The per-SNP results are provided in **Supplementary**
18 **Table 25** and **Supplementary Figures 10**. Because large-scale GWAS of non-BP cardiovascular risk
19 factors are available, we examined the BP risk scores as predictors of other cardiovascular risk factors:
20 LDL-cholesterol, HDL-cholesterol, triglycerides, type 2 diabetes, BMI, and height. We observed nominal
21 ($P < 0.05$) associations of the BP risk scores with risk factors, although mostly in the opposite direction to
22 the risk factor-CVD association (**Supplementary Table 26**). The failure to demonstrate an effect of BP
23 risk scores on heart failure may reflect limited power from a modest sample size, but the lack of
24 significant effects on renal measures suggests that the epidemiologic relationship of higher BP and
25 worse renal function may not reflect direct consequences of BP elevation.

26 **DISCUSSION**

27 The study reported here is the largest to date to investigate the genomics of BP in multiple
28 continental ancestries. Our results highlight four major features of inter-individual variation in BP: (1)
29 we identified 66 (17 novel) genome-wide significant loci for SBP and DBP by targeted genotyping in up
30 to 342,415 individuals of European ancestry that cumulatively explain ~3.5% of the trait; (2) the variants
31 were enriched for *cis*-regulatory elements, particularly in vascular endothelial cells; (3) the variants had

1 broadly comparable BP effects in South Asians, East Asian and Africans, albeit in smaller sample sizes;
2 and, (4) a 66 SNP risk-score predicted target organ damage in the heart, cerebral vessels, carotid artery
3 and the eye with little evidence for an effect in kidneys. Overall, there was no enrichment of a single
4 genetic pathway in our data; rather, our results are consistent with the effects of BP arising from
5 multiple tissues and organs.

6 Genetic and molecular analyses of Mendelian syndromes of hypertension and hypotension point
7 largely to a renal origin, involving multiple rare deleterious mutations in proteins that regulate salt-
8 water balance³⁸. This is strong support for Guyton's hypothesis that the regulation of sodium excretion
9 by the kidney and its effects on extracellular volume are a prime pathway determining intra-arterial
10 pressure³⁹. However, our genetic data from unselected individuals in the general community argues
11 against a single dominant renal effect. The 66 SNPs we identified are not chance effects, but have a
12 global distribution and impact on BP that are consistent as measured by their effects across the many
13 studies meta-analyzed. That they are polymorphic across all continental ancestries argues for their
14 origin and functional effects prior to human continental differentiation.

15 However several of the 17 novel loci contain strong positional biological candidates, these are
16 described in greater detail in **Supplementary Table 27** and the **Supplementary Note**. The single most
17 common feature we identified was the enrichment of regulatory elements for gene expression in
18 vascular endothelial cells. The broad distribution of these cells across both large and small vessels and
19 across all tissues and organs suggest that functional variation in these cells affects endothelial
20 permeability or vascular smooth muscle cell contractility via multiple pathways. These hypotheses will
21 need to be rigorously tested in appropriate models, to assess the contribution of these pathways to BP
22 control, and these pathways could also be targets for systemic anti-hypertensive therapy as they are for
23 the pulmonary circulation⁴².

24 In summary, these genetic observations may contribute to an improved understanding of BP
25 biology and a re-evaluation of the pathways considered relevant for therapeutic BP control.

1 **SUPPLEMENTARY NOTE**

2 Supplementary Note is available in the online version of the paper.

3 **SUMMARY STATISTICS**

4 Full summary statistics (*P* values) are in the online version of the paper (file “ICBPCMfinalMeta.csv.zip”).

5 **URLs**

6 <http://hgdownload.cse.ucsc.edu/goldenPath/hg19/encodeDCC/wgEncodeUwDnase> for enrichment
7 analyses. Accessed 3/13/2013.

8 <http://www.genome.gov/gwastudies> for enrichment analyses. Accessed 3/13/2013.

9 <http://genome.ucsc.edu/ENCODE/cellTypes.html> for enrichment analyses. Accessed 3/13/2013.

10 **ACKNOWLEDGEMENTS**

11 We thank all the study participants of this study for their contributions. Detailed acknowledgment of
12 funding sources is provided in the **Supplementary Note**.

13 **AUTHOR CONTRIBUTIONS**

14 **Analysis group**

15 Design of secondary analyses: G.B.E., T.Ferreira, T.J., A.P.M., P.B.M., C.N.-C. Computation of secondary
16 analyses: G.B.E., T.Ferreira, T.J., A.P.M., P.B.M., C.N.-C. Paper writing: A.C., G.B.E., T.Ferreira, T.J., A.P.M.,
17 P.B.M., C.N.-C. Study management: P.B.M., C.N.-C.

18 **Cardio-MetaboChip or new GWAS**

19 WGHS: Study phenotyping: P.M.R., D.I.C., L.M.R. Genotyping or analysis: P.M.R., D.I.C., L.M.R.,
20 F.Giulianini Study PI: P.M.R.

21 JUPITER: Study phenotyping: P.M.R., D.I.C., L.M.R. Genotyping or analysis: D.I.C., L.M.R., F.Giulianini
22 Study PI: P.M.R., D.I.C.

23 deCODE: Study phenotyping: G.B. Genotyping or analysis: G.T. Study PI: K.S., U.T.

24 GoDARTS: Study phenotyping: C.N.A.P., L.A.D., A.D.M., A.S.F.D. Genotyping or analysis: C.N.A.P., L.A.D.,
25 A.D.M., M.I.M., C.G., N.W.W.R.R. Study PI: C.N.A.P., A.D.M.

26 KORA F3/F4: Study phenotyping: A.D., H.Schunkert, J.E. Genotyping or analysis: A.-K.P., M.M.-N., N.K.,
27 T.I. Study PI: H.-E.W., A.Peters

28 GLACIER: Study phenotyping: F.R., G.H. Genotyping or analysis: P.W.F., D.Shungin, I.B., S.Edkins, F.R.
29 Study PI: P.W.F.

30 B58C: Genotyping or analysis: S.Kanoni, K.E.S., Wellcome Trust Case Control Consortium, E.M.,
31 T.Ferreira, T.J. Study PI: P.D.

32 MORGAM: Study phenotyping: K.Kuulasmaa, F.Gianfagna, A.Wagner, J.Dallongeville Genotyping or
33 analysis: M.F.H., F.Gianfagna Study PI: J.V., J.F., A.E.

34 SardiNIA: Study phenotyping: E.G.L. Genotyping or analysis: E.G.L., O.Meirelles, S.Sanna, R.N., A.Mulas,
35 K.V.T.

1 NFBC1986: Study phenotyping: M.R.J., S.Seibert, K.H.H., A.L.H. Genotyping or analysis: M.Kaakinen,
2 A.L.H. Study PI: M.R.J.
3 DESIR: Genotyping or analysis: N.B.-N., L.Y., S.L. Study PI: P.F., N.B.-N., B.B.
4 DILGOM: Study phenotyping: S.M. Genotyping or analysis: K.Kristiansson, M.P., A.S.H. Study PI: V.S.
5 IMPROVE: Study phenotyping: D.B. Genotyping or analysis: R.J.S., K.G. Study PI: A.Hamsten, E.Tremoli
6 HyperGEN: Study phenotyping: S.C.H., D.C.R. Genotyping or analysis: A.C., V.P., G.B.E. Study PI: S.C.H.
7 FENLAND (MetaboChip): Study phenotyping: R.J.F.L., J.a.L., N.J.W., K.K.O. Genotyping or analysis:
8 R.J.F.L., J.a.L., N.J.W., K.K.O. Study PI: N.J.W.
9 Whitehall II: Study phenotyping: M.Kumari Genotyping or analysis: M.Kumari, S.Shah, C.L. Study PI:
10 A.Hingorani, M.Kivimaki
11 LURIC: Genotyping or analysis: M.E.K., G.Delgado Study PI: W.M.
12 MESA: Study phenotyping: W.P. Genotyping or analysis: W.P., X.G., J.Y., V.D., K.D.T., J.I.R., Y.-D.C. Study
13 PI: W.P.
14 HUNT2: Study phenotyping: K.Kvaløy, J.H., O.L.H. Genotyping or analysis: A.U.J. Study PI: K.H.
15 FINCAVAS: Genotyping or analysis: T.L., L.-P.L., K.N., M.Kähönen Study PI: T.L., M.Kähönen
16 GenNet: Study phenotyping: R.S.C., A.B.W. Genotyping or analysis: A.C., V.P., M.X.S., D.E.A., G.B.E.
17 Study PI: A.C., R.S.C., A.B.W.
18 SCARFSHEEP: Study phenotyping: B.G. Genotyping or analysis: R.J.S. Study PI: A.Hamsten, U.d.F.
19 DPS: Study phenotyping: J.L. Genotyping or analysis: A.U.J., P.S.C. Study PI: J.T., M.U.
20 DR's EXTRA: Study phenotyping: P.K. Genotyping or analysis: A.U.J., M.H. Study PI: R.Rauramaa, T.A.L.
21 FIN-D2D 2007: Genotyping or analysis: A.U.J., L.L.B. Study PI: J.Saltevo, L.M.
22 METSIM: Study phenotyping: H.M.S. Genotyping or analysis: A.U.J., A.Stančáková Study PI: M.L., J.K.
23 MDC-CVA: Study phenotyping: O.Melander Genotyping or analysis: O.Melander, C.F. Study PI:
24 O.Melander
25 BRIGHT: Study phenotyping: A.F.D., M.J.B., N.J.S., J.M.C. Genotyping or analysis: T.J., P.B.M. Study PI:
26 M.J.C., A.F.D., M.J.B., N.J.S., J.M.C., P.B.M.
27 NESDA: Study phenotyping: J.H.S. Genotyping or analysis: H.Snieder, I.M.N. Study PI: B.W.P.
28 EPIC (MetaboChip): Study phenotyping: R.J.F.L., J.a.L., N.J.W. Genotyping or analysis: J.a.L., N.J.W.
29 Study PI: N.J.W., K.-T.K.
30 ELY: Study phenotyping: C.L., J.a.L., N.J.W. Genotyping or analysis: C.L., J.a.L., N.J.W. Study PI: N.J.W.
31 DIAGEN: Study phenotyping: J.G., G.M. Genotyping or analysis: A.U.J., G.M. Study PI: P.E.S., S.R.B.
32 GOSH: Study phenotyping: P.K.M., N.L.P. Genotyping or analysis: E.I., P.K.M., N.L.P., T.Fall Study PI: E.I.
33 Tromsø: Study phenotyping: T.W. Genotyping or analysis: A.U.J., A.J.S., N. Study PI: I.N.
34 ADVANCE: Study phenotyping: T.L.A., C.I. Genotyping or analysis: T.L.A., E.L.S., T.Q. Study PI: T.L.A.,
35 T.Q., C.I.
36 ULSAM: Study phenotyping: E.I., J.Sundstrom Genotyping or analysis: E.I., N.E., J.Sundstrom, A.-C.S.
37 Study PI: J.Sundstrom
38 PIVUS: Study phenotyping: L.Lind, J.Sundstrom Genotyping or analysis: L.Lind, N.E., J.Sundstrom, T.A.
39 Study PI: L.Lind, J.Sundstrom
40 MRC NSHD: Study phenotyping: D.K. Genotyping or analysis: A.Wong, J.a.L., D.K., K.K.O. Study PI: D.K.
41 ASCOT: Study phenotyping: A.Stanton, N.P. Genotyping or analysis: T.J., M.J.C., P.B.M. Study PI: P.S.,
42 M.J.C.
43 THISEAS: Genotyping or analysis: L.S.R., S.Kanoni, E.M., G.Kolovou Study PI: G.Dedoussis, P.D.
44 PARC: Study phenotyping: R.M.K. Genotyping or analysis: K.D.T., E.Theusch, J.I.R., X.L., M.O.G., Y.D.I.C.
45 Study PI: R.M.K.
46 AMC-PAS: Genotyping or analysis: G.K.H., P.D. Study PI: G.K.H.
47 CARDIOGENICS: Genotyping or analysis: S.Kanoni, A.H.G. Study PI: P.D., A.H.G., J.E., N.J.S., H.Schunkert
48 **Secondary analyses**

1 Allele-specific FAIRE: Design of secondary analysis: A.J.P.S. Computation of secondary analysis: A.J.P.S.,
2 F.D., P.H.

3 ASAP eQTL: Design of secondary analysis: A.F.C. Computation of secondary analysis: L.Folkersen,
4 P.Eriksson

5 CARDIOGENICS eQTL: Computation of secondary analysis: L.Lataniotis

6 CM design: P.B.M., C.N.-C., T.J., B.F.V.

7 Comprehensive literature review: Design of secondary analysis: P.B.M. Computation of secondary
8 analysis: K.W., P.B.M.

9 DEPICT: Design of secondary analysis: L.Franke, T.H.P., J.N.H. Computation of secondary analysis: T.H.P.

10 DHS and methylation analysis by tissue: Design of secondary analysis: C.J.W. Computation of secondary
11 analysis: E.M.S.

12 DHS and methylation by cell-line: Design of secondary analysis: D.I.C. Computation of secondary
13 analysis: D.I.C., F.Giulianini

14 FHS eSNP: Design of secondary analysis: R.Joehanes Computation of secondary analysis: R.Joehanes

15 ICBP SC: C.N.-C., M.J.C., P.B.M., A.C., K.M.R., P.-O'R., W.P., D.L., M.D.T., B.M.P., A.D.J., P.Elliott, C.M.v.D.,
16 D.I.C., A.V.S., M.Bochud, L.V.W., H.Snieder, G.B.E.

17 Kidney eQTL: Computation of secondary analysis: H.J.G., S.K.K.

18 MAGENTA: Design of secondary analysis: D.I.C. Computation of secondary analysis: D.I.C.

19 Miscellaneous: Computation of secondary analysis: H.Warren

20 MuTHER eQTL: Design of secondary analysis: P.D. Computation of secondary analysis: L.Lataniotis, T.-
21 P.Y.

22 NESDA eQTL: Design of secondary analysis: R.Jansen Computation of secondary analysis: R.Jansen, A.V.

23 NTR eQTL: Design of secondary analysis: R.Jansen Computation of secondary analysis: R.Jansen, J.-J.H.
24 Study PI: D.I.B.

25 eQTL, EGCUT: Design of secondary analysis: A.Metspalu Computation of secondary analysis: T.E.,
26 A.Metspalu

27 eQTL, Groningen: Design of secondary analysis: L.Franke Computation of secondary analysis: H.J.W.,
28 L.Franke

29 Public eSNP and methylation: Design of secondary analysis: A.D.J., J.D.E. Computation of secondary
30 analysis: A.D.J., J.D.E.

31 PubMed search: Design of secondary analysis: G.B.E. Computation of secondary analysis: G.B.E., L.Lin

32 WGHS conditional: Design of secondary analysis: D.I.C. Computation of secondary analysis: D.I.C.,
33 F.Giulianini, L.M.R.

34 **Lookup of Cardio-MetaboChip variants**

35 HEXA: Genotyping or analysis: Y.J.K., Y.K.K., Y.-A.S. Study PI: J.-Y.L.

36 RACe: Study phenotyping: D.Saleheen, W.Zhao, A.R., A.R. Genotyping or analysis: W.Zhao, A.R., A.R.
37 Study PI: D.Saleheen

38 HALST: Study phenotyping: C.A.H. Genotyping or analysis: J.I.R., Y.-D.C., C.A.H., R.-H.C., I.-S.C. Study PI:
39 C.A.H.

40 CLHNS: Study phenotyping: N.R.L., L.S.A. Genotyping or analysis: Y.W., N.R.L., L.S.A. Study PI: K.L.M.,
41 L.S.A.

42 GxE/Spanish Town: Study phenotyping: B.O.T., C.A.M., R.W. Genotyping or analysis: C.D.P. Study PI:
43 R.S.C., C.A.M., R.W., T.Forrester, J.N.H.

44 DRAGON: Study phenotyping: W.-J.L., W.H.-H.S., K.-W.L., I-Te Lee Genotyping or analysis: J.I.R., Y.-D.C.,
45 E.K., D.A., K.D.T., X.G. Study PI: W.H.-H.S.

46 SEY: Study phenotyping: P.B. Genotyping or analysis: M.Bochud, G.B.E., F.M. Study PI: P.B., M.Bochud,
47 M.Burnier, F.P.

1 TUDR: Study phenotyping: W.H.-H.S., I-Te Lee, W.-J.L. Genotyping or analysis: J.I.R., Y.-D.C., E.K., K.D.T.,
2 X.G. Study PI: W.H.-H.S.

3 TANDEM: Study phenotyping: P.B., M.Bochud Genotyping or analysis: G.B.E., F.M. Study PI: P.B.,
4 M.Bochud, M.Burnier, F.P.

5 **Imputed genotypes**

6 FHS: Study phenotyping: D.L. Genotyping or analysis: D.L. Study PI: D.L.

7 ARIC: Study phenotyping: E.B. Genotyping or analysis: G.B.E., E.B., A.C.M., A.C., S.K.G. Study PI: E.B.,
8 A.C.

9 RS: Genotyping or analysis: G.C.V., A.G.U. Study PI: A.Hofman, A.G.U., O.H.F.D.

10 CoLaus: Study phenotyping: P.V. Genotyping or analysis: Z.K. Study PI: P.V.

11 NFBC1966: Study phenotyping: M.R.J. Genotyping or analysis: P.O.R. Study PI: M.R.J.

12 SHIP: Study phenotyping: R.Rettig Genotyping or analysis: A.T.

13 CHS: Study phenotyping: B.M.P. Genotyping or analysis: K.M.R. Study PI: B.M.P.

14 EPIC (GWAS): Study phenotyping: N.J.W., R.J.F.L., J.a.L. Genotyping or analysis: N.J.W., J.H.Z., J.a.L.
15 Study PI: N.J.W., K.-T.K.

16 SU.VI.MAX: Study phenotyping: S.H. Genotyping or analysis: S.H., P.M. Study PI: P.M.

17 Amish: Genotyping or analysis: M.E.M. Study PI: A.Parsa

18 FENLAND (GWAS): Study phenotyping: N.J.W., J.a.L., R.J.F.L., K.K.O. Genotyping or analysis: N.J.W.,
19 J.a.L., R.J.F.L., K.K.O. Study PI: N.J.W.

20 DGI: Study phenotyping: C.N.C. Genotyping or analysis: C.N.C., G.Kosova Study PI: C.N.C.

21 ERF (EUROSPAN): Genotyping or analysis: N.A. Study PI: C.M.v.D.

22 MIGEN: Study phenotyping: S.Kathiresan, R.E. Genotyping or analysis: S.Kathiresan, R.E. Design of
23 secondary analysis: S.Kathiresan, R.E.

24 MICROS: Study phenotyping: P.P.P. Genotyping or analysis: A.A.H. Study PI: A.A.H., P.P.P.

25 FUSION: Genotyping or analysis: A.U.J. Study PI: M.Boehnke, F.S.C., K.L.M., J.Saramies

26 TwinsUK: Genotyping or analysis: C.M. Study PI: T.D.S.

27 PROCARDIS: Genotyping or analysis: M.Farrall, A.G. Study PI: M.Farrall

28 BLSA: Study phenotyping: L.Ferrucci Genotyping or analysis: T.T. Study PI: L.Ferrucci

29 ORCADES: Study phenotyping: J.F.W. Study PI: J.F.W.

30 Croatia-Vis: Genotyping or analysis: V.V., C.H. Study PI: V.V., C.H.

31 NSPHS: Genotyping or analysis: S.Enroth Study PI: U.G.

32 InCHIANTI: Genotyping or analysis: T.T. Study PI: S.Bandinelli

33 AGES Reykjavik: Study phenotyping: V.G. Genotyping or analysis: A.V.S. Study PI: V.G.

34 **Lookup**

35 CARDIoGRAMplusC4D: Genotyping or analysis: P.D. Study PI: J.Danesh, H.Schunkert, T.L.A., J.E.,
36 S.Kathiresan, R.Roberts, N.J.S., P.D.

37 CHARGE cIMT: Genotyping or analysis: C.O'D., J.C.B.

38 CHARGE EYE: Genotyping or analysis: T.Y.W., X.S., R.A.J. Study PI: T.Y.W.

39 CHARGE-HF consortium: Study phenotyping: R.S.V., J.F.F. Genotyping or analysis: H.L., J.F.F. Study PI:
40 R.S.V.

41 CKDGen: Genotyping or analysis: M.G., V.M.

42 COGENT: Study phenotyping: N.F., J.R. Genotyping or analysis: N.F., X.Z., B.J.K., B.O.T., J.R.

43 EchoGen consortium: Study phenotyping: R.S.V., J.F.F. Genotyping or analysis: H.L., J.F.F. Study PI:
44 R.S.V.

45 KidneyGen Consortium: Study phenotyping: J.C.C., J.S.K., P.Elliott Genotyping or analysis: W.Zhang,
46 J.C.C., J.S.K. Study PI: J.C.C., J.S.K.

47 MetaStroke: Genotyping or analysis: S.Bevan, H.S.M.

48 NeuroCHARGE: Genotyping or analysis: M.Fornage, M.A.I. Study PI: M.A.I.

1 PROMIS: Study phenotyping: D.Saleheen, W.Zhao, J.Danesh Genotyping or analysis: W.Zhao Study PI:
2 D.Saleheen
3 SEED: Study phenotyping: T.Y.W., C.-Y.C. Genotyping or analysis: E.-S.T, C.-Y.C., C.-Y.C. Study PI: C.-Y.C.,
4 T.Y.W.
5 UK Biobank: BP group leaders: Mark Caulfield, P.Elliott Genotyping or analysis: M.R.B., H.Warren,
6 Claudia Cabrera, Evangelos Evangelou, He Gao.

7 **COMPETING FINANCIAL INTERESTS**

8 The authors declare competing financial interests (see corresponding section in the Supplementary
9 Note).
10

1 REFERENCES

- 2 1. Johnson, T. *et al.* Blood Pressure Loci Identified with a Gene-Centric Array. *The American Journal*
3 *of Human Genetics* **89**, 1-13 (2011).
- 4 2. Newton-Cheh, C. *et al.* Association of common variants in NPPA and NPPB with circulating
5 natriuretic peptides and blood pressure. *Nature genetics* **41**, 348-53 (2009).
- 6 3. Franceschini, N. *et al.* Genome-wide association analysis of blood-pressure traits in African-
7 ancestry individuals reveals common associated genes in African and non-African populations.
8 *Am J Hum Genet* **93**, 545-54 (2013).
- 9 4. Ganesh, S.K. *et al.* Effects of long-term averaging of quantitative blood pressure traits on the
10 detection of genetic associations. *Am J Hum Genet* **95**, 49-65 (2014).
- 11 5. Ehret, G.B. *et al.* Genetic variants in novel pathways influence blood pressure and cardiovascular
12 disease risk. *Nature* **478**, 103-109 (2011).
- 13 6. Wain, L.V. *et al.* Genome-wide association study identifies six new loci influencing pulse
14 pressure and mean arterial pressure. *Nat Genet* **43**, 1005-11 (2011).
- 15 7. Newton-Cheh, C. *et al.* Genome-wide association study identifies eight loci associated with
16 blood pressure. *Nat Genet* **41**, 666-76 (2009).
- 17 8. Simino, J. *et al.* Gene-age interactions in blood pressure regulation: a large-scale investigation
18 with the CHARGE, Global BPgen, and ICBP Consortia. *Am J Hum Genet* **95**, 24-38 (2014).
- 19 9. Tragante, V. *et al.* Gene-centric meta-analysis in 87,736 individuals of European ancestry
20 identifies multiple blood-pressure-related loci. *Am J Hum Genet* **94**, 349-60 (2014).
- 21 10. Wang, Y. *et al.* From the Cover: Whole-genome association study identifies STK39 as a
22 hypertension susceptibility gene. *Proc Natl Acad Sci U S A* **106**, 226-31 (2009).
- 23 11. Kato, N. *et al.* Meta-analysis of genome-wide association studies identifies common variants
24 associated with blood pressure variation in east Asians. *Nature genetics* **43**, 531-8 (2011).
- 25 12. Padmanabhan, S. *et al.* Genome-wide association study of blood pressure extremes identifies
26 variant near UMOD associated with hypertension. *PLoS genetics* **6**, e1001177 (2010).
- 27 13. Miall, W.E. & Oldham, P.D. The hereditary factor in arterial blood-pressure. *Br Med J* **1**, 75-80
28 (1963).
- 29 14. Levy, D. *et al.* Framingham Heart Study 100K Project: genome-wide associations for blood
30 pressure and arterial stiffness. *BMC Med Genet* **8 Suppl 1**, S3 (2007).
- 31 15. Teslovich, T.M. *et al.* Biological, clinical and population relevance of 95 loci for blood lipids.
32 *Nature* **466**, 707-13 (2010).
- 33 16. Voight, B.F. *et al.* The metabochip, a custom genotyping array for genetic studies of metabolic,
34 cardiovascular, and anthropometric traits. *PLoS Genet* **8**, e1002793 (2012).
- 35 17. Tobin, M.D., Sheehan, N.A., Scurrah, K.J. & Burton, P.R. Adjusting for treatment effects in studies
36 of quantitative traits: antihypertensive therapy and systolic blood pressure. *Stat Med* **24**, 2911-
37 35 (2005).
- 38 18. Locke, A.E. *et al.* Genetic studies of body mass index yield new insights for obesity biology.
39 *Nature* **518**, 197-206 (2015).
- 40 19. Shungin, D. *et al.* New genetic loci link adipose and insulin biology to body fat distribution.
41 *Nature* **518**, 187-96 (2015).
- 42 20. Sudlow, C. *et al.* UK biobank: an open access resource for identifying the causes of a wide range
43 of complex diseases of middle and old age. *PLoS Med* **12**, e1001779 (2015).
- 44 21. Levy, D. *et al.* Genome-wide association study of blood pressure and hypertension. *Nat Genet*
45 **41**, 677-87 (2009).
- 46 22. Yang, J. *et al.* Conditional and joint multiple-SNP analysis of GWAS summary statistics identifies
47 additional variants influencing complex traits. *Nat Genet* **44**, 369-75, S1-3 (2012).

- 1 23. Yang, J., Lee, S.H., Goddard, M.E. & Visscher, P.M. GCTA: a tool for genome-wide complex trait
2 analysis. *Am J Hum Genet* **88**, 76-82 (2011).
- 3 24. Kimber, C.H. *et al.* TCF7L2 in the Go-DARTS study: evidence for a gene dose effect on both
4 diabetes susceptibility and control of glucose levels. *Diabetologia* **50**, 1186-91 (2007).
- 5 25. Erdmann, J. *et al.* Dysfunctional nitric oxide signalling increases risk of myocardial infarction.
6 *Nature* **504**, 432-6 (2013).
- 7 26. Hirata, Y. *et al.* Mechanisms of adrenomedullin-induced vasodilation in the rat kidney.
8 *Hypertension* **25**, 790-5 (1995).
- 9 27. Epigenomics Roadmap *et al.* Integrative analysis of 111 reference human epigenomes. *Nature*
10 **518**, 317-30 (2015).
- 11 28. Consortium, E.P. An integrated encyclopedia of DNA elements in the human genome. *Nature*
12 **489**, 57-74 (2012).
- 13 29. Maurano, M.T. *et al.* Systematic localization of common disease-associated variation in
14 regulatory DNA. *Science* **337**, 1190-5 (2012).
- 15 30. Welter, D. *et al.* The NHGRI GWAS Catalog, a curated resource of SNP-trait associations. *Nucleic*
16 *Acids Res* **42**, D1001-6 (2014).
- 17 31. Trynka, G. *et al.* Chromatin marks identify critical cell types for fine mapping complex trait
18 variants. *Nat Genet* **45**, 124-30 (2013).
- 19 32. Ernst, J. *et al.* Mapping and analysis of chromatin state dynamics in nine human cell types.
20 *Nature* **473**, 43-9 (2011).
- 21 33. Segre, A.V. *et al.* Common inherited variation in mitochondrial genes is not enriched for
22 associations with type 2 diabetes or related glycemic traits. *PLoS Genet* **6**(2010).
- 23 34. Pers, T.H. *et al.* Biological interpretation of genome-wide association studies using predicted
24 gene functions. *Nat Commun* **6**, 5890 (2015).
- 25 35. Giresi, P.G., Kim, J., McDaniell, R.M., Iyer, V.R. & Lieb, J.D. FAIRE (Formaldehyde-Assisted
26 Isolation of Regulatory Elements) isolates active regulatory elements from human chromatin.
27 *Genome Res* **17**, 877-85 (2007).
- 28 36. Stergachis, A.B. *et al.* Conservation of trans-acting circuitry during mammalian regulatory
29 evolution. *Nature* **515**, 365-70 (2014).
- 30 37. Mancia, G. *et al.* 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task
31 Force for the Management of Arterial Hypertension of the European Society of Hypertension
32 (ESH) and of the European Society of Cardiology (ESC). *Eur Heart J* **34**, 2159-219 (2013).
- 33 38. Lifton, R., Somlo, S., Giebisch, G. & Seldin, D. *Genetic Diseases of the Kidney*, (Academic Press,
34 2009).
- 35 39. Coffman, T.M. & Crowley, S.D. Kidney in hypertension: guyton redux. *Hypertension* **51**, 811-6
36 (2008).
- 37 40. Kim, C.H. *et al.* Mutations in the dopamine beta-hydroxylase gene are associated with human
38 norepinephrine deficiency. *American journal of medical genetics* **108**, 140-7 (2002).
- 39 41. Deinum, J. *et al.* DBH gene variants that cause low plasma dopamine beta hydroxylase with or
40 without a severe orthostatic syndrome. *Journal of medical genetics* **41**, e38 (2004).
- 41 42. Ghofrani, H.A. *et al.* Riociguat for the treatment of pulmonary arterial hypertension. *N Engl J*
42 *Med* **369**, 330-40 (2013).

44

1 **FIGURE LEGENDS**

2 **Figure 1. Manhattan plots for SBP and DBP from the stage 4 Cardio-MetaboChip-wide meta-analysis.**

3 P values (expressed as $-\log_{10}P$) are plotted by physical genomic position labeled by chromosome. SNPs in
4 new loci (3.5MB window around the index SNP), identified in this study, are labeled in dark red (SBP) or
5 dark blue (DBP); SNPs in previously known loci are labeled in orange (SBP) or light blue (DBP). The locus
6 names are indicated. The grey crosses indicate genomic positions at which the y-axis was truncated
7 (SNPs with $P < 10^{-15}$).

8 **Figure 2. Enrichment of DNase hypersensitive sites among BP loci in different cell-types.** Enrichment

9 analyses of SBP or DBP associated loci according to discovery P value using narrow peaks (panel A) or
10 broad peaks (panel B). SNPs were selected according to different P value cutoffs (x-axis) and a fold
11 enrichment of overlap with DNase hypersensitive sites compared to unrelated GWAS SNPs was
12 calculated (y-axis) (see **Supplementary Note**). The 12 endothelial cell-lines are indicated in color and for
13 each endothelial cell-type the rank using the 10^{-14} P value cutoff is indicated. EC denotes endothelial
14 cells.

15 **TABLE LEGENDS**

16 **Table 1. SBP and DBP association at 66 loci.**

17 Meta-analysis results of up to 342,415 individuals of European ancestry for SBP and DBP: Established
18 and new loci are grouped separately. Nearest genes are shown as locus labels but this should not be
19 interpreted as support that the causal gene is the nearest gene. The lead SNP with the lowest P value
20 for either BP trait is shown as the lead SNP and both SBP and DBP results are presented even if both are
21 not genome-wide significant. The SNP effects are shown according to the effect in mm Hg per copy of
22 the coded allele (that is the allele coded 0, 1, 2) under an additive genetic model. "*" in the lead SNP
23 column indicates a non-synonymous coding SNP (either the SNP itself or another SNP in $r^2 > 0.8$). #
24 Established loci have smaller total sample sizes relative to novel loci (see **Supplementary Note**).

25 **Table 2. Overview of novel and known BP variant properties.**

26 Key characteristics of the novel and established BP loci are shown. MAF and effect size estimates are
27 derived from the Cardio-MetaboChip data. Variance explained estimates are estimated from one large
28 study (**Supplementary Note**). Novel loci are classified as previously unknown to be linked to BP by a
29 systematic PubMed review of all genes in a 200kb window (**Supplementary Note**).

30

1 **Table 3. Prediction of hypertensive target organ damage by a multi-BP SNP score.**

2 Shown are the estimated effects of a BP risk score comprised of up to 66 SNPs (see column “Total
3 #SNPs”) on risk of dichotomous outcome (as odds ratios) or increment in continuous measures per
4 predicted mmHg of the SBP or DBP score. The effect sizes are expressed as incremental change in the
5 phenotype for quantitative traits and natural logarithm of the odds ratio for binary traits, per 1 mmHg
6 predicted increase in SBP or DBP. *P* values are bolded if they meet an analysis-wide significance
7 threshold ($< 0.05/18 = 0.0028$). Results for all SNPs (“all”) and for pruned results (“p”) are shown. The
8 pruned results were obtained by iterative removal of SNPs from the risk score starting with the SNP with
9 lowest heterogeneity *P* value. Iterations to remove SNPs were continued until the heterogeneity *P* value
10 was < 0.0028 (see **Supplementary Note**). The number of SNPs removed when calculating the pruned
11 results is indicated by “# SNPs rem.”. The results per individual SNP can be found in **Supplementary**
12 **Table 15**. CAD: coronary artery disease, LV: left ventricle, CKD: chronic kidney disease, eGFR: estimated
13 glomerular filtration rate, cr: creatinine, cIMT: carotid intima: media thickness. Var. type denotes the
14 variable type and cont. for continuous, or dic. for dichotomous. Eth. = Ethnicity, Consort. = Consortium,
15 EUR = European ancestry, EAS = East Asian ancestry.

16

1 Table 1. New and known BP loci.

Locus no.	Locus name	Lead SNP	Chr	Position (hg19)	CA /NC	Coded allele freq	Traits	SBP				DBP			
								Effect	SE	P value	Total N	Effect	SE	P value	Total N#
NEW 1	HIVEP3	rs7515635	1	42,408,070	T/C	0.468	SBP	0.307	0.0444	4.81E-12	340,969	0.1365	0.0263	2.05E-07	340,934
NEW 2	PNPT1	rs1975487	2	55,809,054	A/G	0.464	DBP	-0.2107	0.045	2.81E-06	337,522	-0.1602	0.0266	1.75E-09	337,517
NEW 3	FGD5	rs11128722	3	14,958,126	A/G	0.563	SBP & DBP	-0.3103	0.0469	3.61E-11	310,430	-0.1732	0.0279	5.16E-10	310,429
NEW 4	ADAMTS9	rs918466	3	64,710,253	A/G	0.406	DBP	-0.0865	0.0459	5.94E-02	336,671	-0.1819	0.027	1.73E-11	336,653
NEW 5	TBC1D1-FLJ13197	rs2291435	4	38,387,395	T/C	0.524	SBP & DBP	-0.3441	0.0449	1.90E-14	331,382	-0.156	0.0266	4.26E-09	331,389
NEW 6	TRIM36	rs10077885	5	114,390,121	A/C	0.501	SBP & DBP	-0.284	0.0444	1.64E-10	338,328	-0.1735	0.0263	3.99E-11	338,323
NEW 7	CSNK1G3	rs6891344	5	123,136,656	A/G	0.819	DBP	0.2811	0.058	1.24E-06	338,688	0.2311	0.0343	1.58E-11	338,678
NEW 8	CHST12-LFNG	rs2969070	7	2,512,545	A/G	0.639	SBP & DBP	-0.2975	0.0464	1.44E-10	335,991	-0.1821	0.0274	2.92E-11	335,972
NEW 9	ZC3HC1	rs11556924	7	129,663,496	T/C	0.384	SBP & DBP	-0.2705	0.0468	7.64E-09	325,929	-0.2141	0.0276	8.15E-15	325,963
NEW 10	PSMD5	rs10760117	9	123,586,737	T/G	0.415	SBP	0.283	0.0457	6.10E-10	333,377	0.0999	0.0269	2.08E-04	333,377
NEW 11	DBH	rs6271*	9	136,522,274	T/C	0.072	SBP & DBP	-0.5911	0.0899	4.89E-11	306,394	-0.4646	0.0532	2.42E-18	306,463
NEW 12	RAPSN, PSMC3, SLC39A13	rs7103648	11	47,461,783	A/G	0.614	SBP & DBP	-0.3349	0.0462	4.43E-13	335,614	-0.2409	0.0272	9.03E-19	335,592
NEW 13	LRRC10B	rs751984	11	61,278,246	T/C	0.879	SBP & DBP	0.4074	0.0691	3.80E-09	334,583	0.3755	0.0409	4.20E-20	334,586
NEW 14	SETBP1	rs12958173	18	42,141,977	A/C	0.306	SBP & DBP	0.3614	0.0489	1.43E-13	331,007	0.1789	0.0289	5.87E-10	331,010
NEW 15	INSR	rs4247374	19	7,252,756	T/C	0.143	SBP & DBP	-0.5933	0.0673	1.23E-18	302,458	-0.3852	0.0396	2.08E-22	302,459
NEW 16	ELAVL3	rs17683167	19	11,584,818	T/C	0.047	DBP	-0.4784	0.1066	7.13E-06	333,137	-0.3479	0.0632	3.71E-08	333,107
NEW 17	CRYAA-SIK1	rs12627651	21	44,760,603	A/G	0.288	SBP & DBP	0.3905	0.0513	2.69E-14	310,738	0.2037	0.0301	1.36E-11	310,722
EST 1	CASZ1	rs880315	1	10,796,866	T/C	0.641	SBP & DBP	-0.475	0.062	2.09E-14	184,226	-0.257	0.038	1.34E-11	184,212
EST 2	MTHFR-NPPB	rs17037390	1	11,860,843	A/G	0.155	SBP & DBP	-0.908	0.081	5.95E-29	195,493	-0.499	0.05	1.20E-23	195,481
EST 3	ST7L-CAPZA1-MOV10	rs1620668	1	113,023,980	A/G	0.822	SBP & DBP	-0.535	0.076	1.45E-12	197,966	-0.285	0.047	9.00E-10	197,948
EST 4	MDM4	rs4245739	1	204,518,842	A/C	0.737	DBP	0.326	0.068	1.37E-06	191,594	0.243	0.041	4.63E-09	191,578
EST 5	AGT	rs2493134*	1	230,849,359	T/C	0.579	SBP & DBP	-0.413	0.058	9.65E-13	199,505	-0.275	0.036	9.53E-15	199,502
EST 6	KCNK3	rs2586886	2	26,932,031	T/C	0.599	SBP & DBP	-0.404	0.059	5.94E-12	197,269	-0.254	0.036	1.92E-12	197,272
EST 7	NCAPH	rs772178	2	96,963,684	A/G	0.64	DBP	-0.072	0.061	2.39E-01	192,513	-0.208	0.038	3.58E-08	192,501
EST 8	FIGN-GRB14	rs1371182	2	165,099,215	T/C	0.443	SBP & DBP	-0.444	0.058	1.89E-14	196,262	-0.252	0.036	1.50E-12	196,240
EST 9	HRH1-ATG7	rs2594992	3	11,360,997	A/C	0.607	SBP	-0.334	0.06	2.31E-08	189,895	-0.136	0.037	2.20E-04	189,854
EST 10	SLC4A7	rs711737	3	27,543,655	A/C	0.604	SBP	0.334	0.058	9.93E-09	200,282	0.17	0.036	2.24E-06	200,260
EST 11	ULK4	rs2272007*	3	41,996,136	T/C	0.18	DBP	-0.11	0.077	1.52E-01	193,915	0.328	0.047	3.94E-12	193,900
EST 12	MAP4	rs6442101*	3	48,130,893	T/C	0.692	SBP & DBP	0.396	0.062	1.62E-10	200,543	0.303	0.038	1.60E-15	200,534
EST 13	MECOM	rs6779380	3	169,111,915	T/C	0.539	SBP & DBP	-0.439	0.06	1.85E-13	186,535	-0.239	0.037	6.67E-11	186,521
EST 14	FGF5	rs1458038	4	81,164,723	T/C	0.3	SBP & DBP	0.659	0.065	5.36E-24	188,136	0.392	0.04	7.36E-23	188,088
EST 15	ARHGAP24	rs17010957	4	86,719,165	T/C	0.857	SBP	-0.498	0.082	1.51E-09	196,325	-0.173	0.051	6.63E-04	196,292
EST 16	SLC39A8	rs13107325	4	103,188,709	T/C	0.07	SBP & DBP	-0.837	0.127	4.69E-11	175,292	-0.602	0.078	1.63E-14	175,372
EST 17	GUCY1A3-GUCY1B3	rs46491707	4	156,441,314	A/G	0.652	SBP	-0.349	0.06	7.10E-09	198,246	-0.163	0.037	1.08E-05	198,226
EST 18	NPR3-C5orf23	rs12656497	5	32,831,939	T/C	0.403	SBP & DBP	-0.487	0.06	3.85E-16	194,831	-0.228	0.037	4.73E-10	194,829
EST 19	EBF1	rs11953630	5	157,845,402	T/C	0.366	SBP & DBP	-0.38	0.065	3.91E-09	167,698	-0.23	0.04	8.07E-09	167,708
EST 20	HFE	rs1799945*	6	26,091,179	C/G	0.857	SBP & DBP	-0.598	0.086	3.28E-12	185,306	-0.43	0.053	3.10E-16	185,273
EST 21	BAT2-BAT5	rs2187668	6	32,605,884	T/C	0.126	DBP	-0.291	0.092	1.60E-03	189,806	-0.372	0.057	4.31E-11	189,810
EST 22	ZNF318-ABCC10	rs6919440	6	43,352,898	A/G	0.57	SBP	-0.337	0.058	4.92E-09	200,733	-0.125	0.035	4.25E-04	200,730
EST 23	RSPO3	rs1361831	6	127,181,089	T/C	0.541	SBP & DBP	-0.482	0.058	7.38E-17	197,027	-0.271	0.036	2.34E-14	197,012
EST 24	PLEKHG1	rs17080093	6	150,997,440	T/C	0.075	DBP	-0.564	0.111	3.83E-07	194,728	-0.411	0.068	1.71E-09	194,734
EST 25	HOTTIP-EVX	rs3735533	7	27,245,893	T/C	0.081	SBP & DBP	-0.798	0.106	6.48E-14	197,881	-0.445	0.065	1.09E-11	197,880
EST 26	PIK3CG	rs12705390	7	106,410,777	A/G	0.227	SBP	0.619	0.069	2.69E-19	198,297	0.059	0.042	1.63E-01	198,290
EST 27	BLK-GATA4	rs2898290	8	11,433,909	T/C	0.491	SBP	0.377	0.058	8.85E-11	197,759	0.167	0.036	3.17E-06	197,726
EST 28	CACNB2	rs12243859	10	18,740,632	T/C	0.326	SBP & DBP	-0.402	0.061	6.13E-11	199,136	-0.335	0.038	8.11E-19	199,124
EST 29	C10orf107	rs7076398	10	63,533,663	A/T	0.188	SBP & DBP	-0.563	0.076	1.72E-13	187,013	-0.409	0.047	2.55E-18	187,024
EST 30	SYNPO2L	rs12247028	10	75,410,052	A/G	0.611	SBP	-0.364	0.063	8.16E-09	180,194	-0.159	0.039	3.89E-05	180,094
EST 31	PLCE1	rs932764*	10	95,895,940	A/G	0.554	SBP & DBP	-0.495	0.059	6.88E-17	195,577	-0.224	0.036	6.28E-10	195,547
EST 32	CYP17A1-NT5C2	rs943037	10	104,835,919	T/C	0.087	SBP & DBP	-1.133	0.105	2.35E-27	193,818	-0.482	0.064	4.48E-14	193,799
EST 33	ADRB1	rs740746	10	115,792,787	A/G	0.73	SBP & DBP	0.486	0.067	4.59E-13	184,835	0.32	0.041	8.63E-15	184,868
EST 34	LSP1-TNNT3	rs592373	11	1,890,990	A/G	0.64	SBP & DBP	0.484	0.063	2.02E-14	177,149	0.282	0.039	3.61E-13	177,134
EST 35	ADM	rs1450271	11	10,356,115	T/C	0.468	SBP & DBP	0.413	0.059	3.40E-12	191,246	0.199	0.036	4.11E-08	191,221
EST 36	PLEKHA7	rs1156725	11	16,307,700	T/C	0.804	SBP & DBP	-0.447	0.072	5.65E-10	200,889	-0.292	0.044	3.67E-11	200,899
EST 37	SIPA1	rs3741378*	11	65,408,937	T/C	0.137	SBP	-0.486	0.084	8.04E-09	194,563	-0.183	0.052	4.17E-04	194,551
EST 38	FLJ32810-TMEM133	rs633185	11	100,593,538	C/G	0.715	SBP & DBP	0.522	0.067	6.97E-15	183,845	0.288	0.041	2.38E-12	183,825
EST 39	PDE3A	rs3752728	12	20,192,972	A/G	0.737	DBP	0.331	0.066	4.32E-07	200,440	0.319	0.04	2.35E-15	200,408
EST 40	ATP2B1	rs11105354	12	90,026,523	A/G	0.84	SBP & DBP	0.909	0.081	3.88E-29	195,206	0.459	0.05	2.61E-20	195,195
EST 41	SH2B3	rs3184504*	12	111,884,608	T/C	0.475	SBP & DBP	0.498	0.062	9.97E-16	177,067	0.362	0.038	1.28E-21	177,122
EST 42	TBX5-TBX3	rs2891546	12	115,552,499	A/G	0.11	DBP	-0.529	0.1	1.36E-07	172,012	-0.38	0.061	4.71E-10	171,980
EST 43	CYP11A1-ULK3	rs936226	15	75,069,282	T/C	0.722	SBP & DBP	-0.549	0.067	3.06E-16	187,238	-0.363	0.041	1.03E-18	187,221
EST 44	FURIN-FES	rs2521501	15	91,437,388	A/T	0.684	SBP & DBP	-0.639	0.069	3.35E-20	164,272	-0.358	0.042	1.85E-17	164,255
EST 45	PLCD3	rs7213273	17	43,155,914	A/G	0.658	SBP	-0.413	0.066	4.71E-10	164,795	-0.185	0.041	7.23E-06	164,788
EST 46	GOSR2	rs17608766	17	45,013,271	T/C	0.854	SBP	-0.658	0.083	2.27E-15	188,895	-0.218	0.051	1.95E-05	188,928
EST 47	ZNF652	rs12940887	17	47,402,807	T/C	0.38	DBP	0.321	0.06	7.06E-08	192,546	0.261	0.037	1.07E-12	192,524
EST 48	JAG1	rs1327235	20	10,969,030	A/G	0.542	SBP & DBP	-0.395	0.059	2.23E-11	192,680	-0.308	0.036	1.78E-17	192,659
EST 49	GNAS-EDN3	rs6026748	20	57,745,815	A/G	0.125	SBP & DBP	0.867	0.089	3.15E-22	192,338	0.552	0.055	4.86E-24	192,327

Table 2. Overview of novel and known BP variant properties.

	17 new loci	49 established loci	66 loci
Minor allele frequency (mean, range)	32.1% [5%-50%]	28.9% [7%-49%]	29.8% [5%-50%]
Effect size SBP [mmHg] (range, mean)	0.09-0.59, 0.34	0.07-1.13, 0.5	0.07-1.13, 0.46
Effect size DBP [mmHg] (range, mean)	0.1-0.46, 0.23	0.06-0.60, 0.3	0.06-0.6, 0.28
Variance explained SBP	0.52%	2.95%	3.46%
Variance explained DBP	0.58%	2.78%	3.36%

Table 3. BP risk score effects on disease outcomes.

Phenotype	Var. type (cont./dic.)	Eth.	Consort.	Total N or no. ca/co	Total #SNPs	SBP_score					DBP_score				
						effect (all)	P value (all)	het. P value (all)	P value (p)	# SNPs rem.	effect (all)	P value (all)	het. P value (all)	P value (p)	# SNPs rem.
HEART															
CAD	dich.	EUR	CARDIoG SAS	63,746 /130,681	61	1.042	1.72E-44	1.75E-25	4.08E-32	10	1.069	1.19E-42	6.63E-27	2.2E-38	10
heart failure	dich.	EUR	CHARGE	2,526 /18,400	66	1.021	2.77E-02	1.63E-01	2.77E-02	0	1.035	2.31E-02	1.70E-01	2.31E-02	0
LV mass	cont.	EUR	CHARGE	11,273	66	0.480	6.43E-04	3.58E-01	6.43E-04	0	0.754	1.23E-03	3.21E-01	1.23E-03	0
LV wall thickness	cont.	EUR	CHARGE	11,311	66	0.004	4.45E-06	5.83E-02	4.45E-06	0	0.007	3.19E-06	6.40E-02	3.19E-06	0
KIDNEY															
CKD	dich.	EUR	CHARGE	6,271 /68,083	65	1.010	1.37E-01	1.77E-03	2.65E-01	1	1.008	4.49E-01	1.25E-03	7.69E-01	1
eGFR (based on cr)	cont.	EUR	CHARGE	74,354	65	0.000	7.07E-01	3.12E-05	3.22E-01	2	0.000	9.41E-01	3.02E-05	9.65E-01	2
eGFR (based on cystatin creatinine)	cont.	EUR	CHARGE	74,354	65	0.001	9.05E-02	9.28E-06	4.11E-01	1	0.001	3.30E-01	5.64E-06	6.9E-01	1
microalbuminuria	dich.	EUR	KidneyGEN	23,812	66	0.000	9.42E-01	6.31E-03	9.42E-01	0	0.000	4.11E-01	7.16E-03	4.11E-01	0
urinary albumin/cr ratio	cont.	EUR	CHARGE	2,499 /29,081	65	0.011	2.10E-01	4.79E-02	2.1E-01	0	0.023	1.02E-01	5.66E-02	1.02E-02	0
urinary albumin/cr ratio	cont.	EUR	CHARGE	31,580	65	0.009	2.52E-03	3.02E-04	0.53E-03	1	0.015	2.40E-03	3.08E-04	8.31E-03	1
STROKE															
stroke, all subtypes	dich.	EUR	CHARGE	1,544 /18,058	66	0.056	6.11E-06	8.26E-02	6.11E-06	0	0.085	3.79E-05	4.98E-02	3.79E-05	0
stroke, ischemic subtype	dich.	EUR	CHARGE	1,164 /18,438	66	0.067	3.33E-06	1.75E-01	3.33E-06	0	0.096	5.63E-05	8.82E-02	5.63E-05	0
stroke, ischemic subtype	dich.	EUR	MetaStroke	11,012 /40,824	66	0.036	1.69E-10	4.72E-02	1.69E-10	0	0.056	1.29E-09	2.51E-02	1.29E-09	0
VASCULATURE															
clMT	cont.	EUR	CHARGE	27,610	66	0.004	4.80E-15	5.06E-08	7.32E-10	4	0.005	4.15E-11	3.84E-10	6.2E-07	5
EYE															
mild retinop.	dich.	EUR	CHARGE	1,122 /18,289	66	1.021	1.37E-01	6.01E-03	1.37E-01	0	1.046	5.78E-02	7.81E-03	5.78E-02	0
central retinal artery caliber	cont.	EUR	CHARGE	18,576	66	0.343	3.29E-14	2.56E-06	2.06E-13	2	0.570	3.61E-14	2.44E-06	7.05E-13	3
mild retinop.	dich.	EAS	SEED	289 /5,419	66	1.033	2.55E-01	2.42E-01	2.55E-01	0	1.087	8.55E-02	2.87E-01	8.55E-02	0
central retinal artery caliber	cont.	EAS	SEED	6,976	63	0.320	1.39E-04	9.07E-01	1.39E-04	0	0.533	2.19E-04	8.91E-01	2.19E-04	0

ONLINE METHODS

Cohorts contributing to systolic (SBP) and diastolic blood pressure (DBP) analyses

Studies contributing to BP association discovery including community- and population-based collections as well as studies of non-BP traits, analyzed as case and control samples separately. Details on each of the studies including study design and BP measurement are provided in **Supplementary Table 1**, genotyping information in **Supplementary Table 2**, and participant characteristics in **Supplementary Table 3**. All participants provided written informed consent and the studies were approved by local Research Ethics Committees and/or Institutional Review Boards.

European ancestry meta-analysis

BP was measured using standardized protocols in all studies regardless of whether the primary focus was BP or another trait. We initially analyzed affected and unaffected individuals from samples selected as cases (e.g. type 2 diabetes) or controls, separately. However, because sensitivity analyses did not reveal any significant difference in BP effect size estimates between case and control samples (data not shown), we analyzed all samples combined. When available, the average of two BP measurements was used for association analyses (**Supplementary Table 1**). If an individual was taking a BP-lowering treatment, the underlying systolic BP (SBP) and diastolic BP (DBP) were estimated by adding 15 mmHg and 10 mmHg, respectively, to the measured values, as done in prior analyses.

A meta-analysis of 340,934 individuals of European descent was undertaken in four stages with subsequent validation in an independent cohort. Because stage 1 Cardio-MetaboChip samples included many SNPs selected on the basis of association with BP in earlier GWAS, we performed genomic control using a set of putative null SNPs based on $P > 0.10$ in earlier GWAS of SBP and DBP or both. Stage 2 samples with genome-wide genotyping used the entire genome-wide set of SNPs for genomic control given the lack of ascertainment. The study design is summarized in **Supplementary Figure 1**, and further details are provided in **Supplementary Tables 2-5** and the **Supplementary Note**.

Systematic PubMed search +/- 100kb of each newly discovered index SNP

All genes with any overlap with a 200kb region centered around each of the 17 newly discovered lead SNPs were identified using the UCSC Genome Browser. A search term was constructed for each gene including the short and long gene name and the terms “blood pressure” and “hypertension” (e.g. for *NPPA* on chr 1: “NPPA OR natriuretic peptide A AND (blood pressure OR hypertension)”) and the search results of each search term from PubMed were individually reviewed.

Trait variance explained

The trait variance explained by 66 lead SNPs at novel and known loci was evaluated in one study that contributed to the discovery effort: the Atherosclerosis Risk in Communities (ARIC) study. We constructed a linear regression model with all 66 or the subset of 49 known SNPs as a set of predictors of the BP residual after adjustment for covariates of the adjusted treatment-corrected BP phenotype (SBP or DBP). The r^2 from the regression model was used as the estimate of trait variance explained.

European ancestry GCTA-COJO analysis

To identify multiple distinct association signals at any given BP locus, we undertook approximate conditional analyses using a model selection procedure implemented in the GCTA-COJO software package^{44,45}. To evaluate the robustness of the GCTA-COJO results to the choice of reference data set, model selection was performed using the LD between variants in separate analyses from two datasets of European descent, both with individuals from the UK with Cardio-MetaboChip genotype data: GoDARTS with 7,006 individuals and WTCCC1-T2D/58BC with 2,947 individuals. Assuming that the LD between

SNPs more than 10 Mb away or on different chromosomes is zero, we undertook the GCTA-COJO step-wise model selection to select SNPs that were conditionally-independently associated with SBP and DBP, in turn, at a genome-wide significance, given by $P < 5 \times 10^{-8}$ (**Supplementary Tables 6-8**) using the stage 4 combined European GWAS+ Cardio-MetaboChip meta-analysis.

Conditional analyses in the Women's Genome Health Study (WGHS)

Multivariable regression modeling was performed for each possible combination of putative independent SNPs from a) model selection implemented in GCTA-COJO and b) a comprehensive manual review of the literature (**Supplementary Table 9**). Any SNP with $P < 5 \times 10^{-8}$ in a previous reported BP GWAS was considered. A total of 46 SNPs were examined (**Supplementary Table 10**). Genome-wide genotyping data imputed to 1000 Genomes in the WGHS ($N = 23,047$) were used. Regression modeling was performed in the R statistical language (**Supplementary Table 10**).

Fine mapping and determination of credible sets of causal SNPs

The GCTA-COJO and WGHS conditional analyses identified multiple distinct signals of association at multiple loci (**Supplementary Tables 6 and 10**). Of the 24 loci considered in fine-mapping analyses, 16 had no evidence for the existence of multiple distinct association signals, so it is reasonable to assume that there is a single causal SNP and therefore the credible sets of variants could be constructed using the association summary statistics from the unconditional meta-analyses. However, in the remaining eight loci, where evidence of secondary signals was observed from GCTA-COJO, we performed approximate conditional analyses across the region by conditioning on each index SNP (**Supplementary Table 11**). By adjusting for the other index SNPs at the locus, we can therefore assume a single variant is driving each "conditionally-independent" association signal, and we can construct the 99% credible set of variants on the basis of the approximate conditional analysis from GCTA-COJO (**Supplementary Tables 12-13**). At five of the eight loci with multiple distinct signals of association, one index SNP mapped outside of the fine-mapping region, so a credible set could not be constructed.

eQTL analysis: Whole Blood

NESDA/NTR: Whole blood eQTL analyses were performed in samples from the Netherlands Study of Depression and Anxiety (NESDA)⁴⁶ and the Netherlands Twin Registry (NTR)⁴⁷ studies. RNA expression analysis was performed in the statistical software R. The residuals resulting from the linear regression analysis of the probe set intensity values onto the covariates sex, age, body mass index (kg/m^2), smoking status coded as a categorical covariate, several technical covariates, and three principal components were used. The eQTL effects were detected using a linear mixed model approach, including for each probe set the expression level (normalized, residualized and without the first 50 expression PCs) as dependent variable; the SNP genotype values as fixed effects; and family identifier and zygosity (in the case of twins) as random effects to account for family and twin relations⁴⁸.

The eQTL effects were defined as *cis* when probe set-SNP pairs were at distance $< 1\text{M}$ base pairs. At a FDR of 0.01 applied genome-wide, not just for candidate SNPs, the P value threshold was 1×10^{-4} for the *cis*-eQTL analysis. For each probe set that displayed a statistically significant association with at least one SNP located within its *cis* region, we identified the most significantly associated SNP and denoted this as the top *cis*-eQTL SNP. See **Supplementary Note** for details.

eQTL analysis: Selected published eQTL datasets

Lead BP SNP and proxies ($r^2 > 0.8$) were searched against a collected database of expression SNP (eSNP) results. The reported eSNP results met criteria for statistical thresholds for association with gene transcript levels as described in the original papers. The non-blood cell tissue eQTLs searched included

aortic endothelial cells⁴⁹, left ventricle of the heart⁵⁰, cd14+ monocytes⁵¹ and the brain⁵². The results are presented in **Supplementary Tables 14-15**.

Enrichment analyses: Analysis of cell-specific DNase hypersensitivity sites (DHSs) using an OR method

The overlap of Cardio-MetaboChip SNPs with DHSs was examined using publicly available data from the Epigenomics Roadmap Project and ENCODE, choosing different cutoffs of Cardio-MetaboChip P values. The DHS mappings were available for 123 mostly adult cells and tissues⁵³ (downloaded from The DHS mappings were specified as both “narrow” and “broad” peaks, referring to reduction of the experimental data to peak calls at 0.1% and 1.0% FDR thresholds, respectively. Thus, the “narrow” peaks are largely nested within the “broad” peaks. Experimental replicates of the DHS mappings (typically duplicates) were also available for the majority of cells and tissues.

SNPs from the Cardio-MetaboChip genome-wide scan were first clumped in PLINK in windows of 100kb and maximum $r^2 = 0.1$ among LD relationships from the 1000 Genomes European data. Then, the resulting index SNPs at each P value threshold were tagged with $r^2 = 0.8$ in windows of 100kb, again using LD relationships in the 1000 Genomes, restricted to SNPs with MAF > 1% and also present in the HapMap2 CEU population. A reference set of SNPs was constructed using the same clumping and tagging procedures applied to GWAS catalog SNPs (available at <http://www.genome.gov/gwastudies/>, accessed 3/13/2013)⁵⁴ with discovery $P < 5 \times 10^{-8}$ in European populations. A small number of reference SNPs or their proxies overlapping the BP SNPs or their proxies were excluded. After LD pruning and exclusions, there were a total of 1,196 reference SNPs. For each cell type and P value threshold, the enrichment of SBP or DBP SNPs (or their LD proxies) mapping to DHSs was expressed as an odds ratio (OR) relative to the GWAS catalog reference SNPs (or their LD proxies), using logistic mixed effect models treating the replicate peak determinations as random effects (glmer package in R). The significance of the enrichment ORs was derived from the significance of beta coefficients for the main effects in the mixed models (**Figure 2, Supplementary Table 16**).

Enrichment analyses: Analysis of tissue-specific enrichment of BP variants and H3K4me3 sites

An analysis to test for significant cell-specific enrichment in the overlap of BP SNPs (or their proxies) with H3K4me3 sites was performed as described in Trynka et al, 2013⁵⁵. The measure of overlap is a “score” that is constructed by dividing the height of an H3K4me3 ChIP signal in a particular cell by the distance between the nearest test SNP. The significance of the scores (i.e. P value) for all SNPs was determined by a permutation approach that compares the observed scores to scores of SNPs with similar properties to the test SNPs, essentially in terms of LD and proximity to genes (**Supplementary Note**). The number of permutations determined the number of significant digits in the P values and we conducted 10,000 iterations. Results are shown in **Supplementary Table 19**.

Enrichment analyses: Analysis of tissue-specific DHSs and chromatin states using GREGOR

The DNase-seq ENCODE data for all available cell types were downloaded in the processed “narrowPeak” format. The local maxima of the tag density in broad, variable-sized “hotspot” regions of chromatin accessibility were thresholded at FDR 1% with peaks set to a fixed width of 150bp. Individual cell types were further grouped into 41 broad tissue categories by taking the union of DHSs for all related cell types and replicates. For each GWAS locus, a set of matched control SNPs was selected based on three criteria: 1) number of variants in LD ($r^2 > 0.7$; ± 8 variants), 2) MAF ($\pm 1\%$), and 3) distance to nearest gene ($\pm 11,655$ bp). To calculate the distance to the nearest gene, the distance to the 5' flanking gene (start and end position) and to the 3' flanking gene was calculated and the minimum of these 4 values was used. If the SNP fell within the transcribed region of a gene, the distance was 0. The probability that a set of GWAS loci overlap with a regulatory feature more often than we expect by chance was estimated.

Enrichment analyses: FAIRE analysis of BP variants in fine-mapping regions in lymphoblastoid cell lines

FAIRE analysis was performed on a sample of 20 lymphoblastoid cell lines of European origin. All samples were genotyped using the Cardio-MetaboChip genotyping array, and BP SNPs and LD proxies ($r^2 > 0.8$) at the fine mapping loci ($N = 24$, see **Supplementary Table 23**) were assessed to identify heterozygous imbalance between non-treated and FAIRE-treated chromatin. A paired t-test was used to compare the B allele frequency (BAF) arising from formaldehyde-fixed chromatin sheared by sonication and DNA purified to the BAF when the same chromatin sample underwent FAIRE to enrich for open chromatin. Three hundred and fifty-seven Cardio-MetaboChip BP SNPs were directly genotyped across the fine mapping regions. The Bonferroni-corrected threshold of significance is $P < 0.0001$ (0.05/357). The results for SNPs with $P < 0.05$ are reported in (**Supplementary Table 23**). FAIRE results were not available for some SNPs with missing data due to genotype failure or not having >3 heterozygous individuals for statistical analysis. Therefore there are no results for three lower frequency BP loci (*SLC39A8*, *CYP17A1-NT5C2* and *GNAS-EDN3*) and for the second signal at the following loci: *MTHFR-NPPB* (rs2272803), *MECOM* (rs2242338) and *HFE* rs1800562).

Pathway analyses: MAGENTA

MAGENTA tests for enrichment of gene sets from a precompiled library derived from GO, KEGG, PATHTER, REACTOME, INGENUITY, and BIOCARTA was performed as described by Segré et al, 2010⁵⁶. Enrichment of significant gene-wide P values in gene sets is assessed by 1) using LD and distance criteria to define the span of each gene, 2) selecting the smallest P value among SNPs mapping to the gene span, and 3) adjusting this P value using a regression method that accounts for the number of SNPs, the LD, etc. In the second step, MAGENTA examines the distribution of these adjusted P values and defines thresholds for the 75%ile and the 95%ile. In the third step, MAGENTA calculates an enrichment for each gene set by comparing the number of genes in the gene set with P value less than either the 75th or 95th %ile to the number of genes in the gene set with P value greater than either the 75th or 95th %ile, and then comparing this quotient to the same quotient among genes not in the gene set. This gene-set quotient is assigned a P value based on reference to a hypergeometric distribution. The results based on our analyses are indicated in **Supplementary Table 21**.

Pathway analyses: DEPICT

We applied the DEPICT⁵⁷ analysis separately on genome-wide significant loci from the overall blood pressure (BP) Cardio-MetaboChip analysis including published blood pressure loci (see **Supplementary Table 22**). SNPs at the *HFE* and *BAT2-BAT5* loci (rs1799945, rs1800562, rs2187668, rs805303, rs9268977) could not be mapped. As a secondary analysis, we additionally included associated loci ($P < 1 \times 10^{-5}$) from the Cardio-MetaboChip stage 4 combined meta-analyses of SBP and the DBP. DEPICT assigned genes to associated regions if they overlapped or resided within associated LD blocks with $r^2 > 0.5$ to a given associated SNP.

Literature review for genes at the newly discovered loci

Recognizing that the most significantly associated SNP at a locus may not be located in the causal gene and that the functional consequences of a SNP often extends beyond 100kb, we conducted a literature review of genes in extended regions around newly discovered BP index SNPs. The genes for this extensive review were identified by DEPICT (**Supplementary Table 22**).

Non-European meta-analysis

To assess the association of the 66 significant loci from the European ancestry meta-analysis in non-European ethnicities, we obtained lookup results for the 66 index SNPs for participants of South-Asian ancestry (8 datasets, total $N = 20,875$), East-Asian ancestry (5 datasets, total $N = 9,637$), and African- and

African-American ancestry (6 datasets, total N = 33,909). The association analyses were all conducted with the same covariates (age, age², sex, BMI) and treatment correction (+15/10 mm Hg in the presence of any hypertensive medication) as the association analyses for the discovery effort in Europeans. Tests for heterogeneity across effect estimates in European, South Asian, East Asian and African derived samples were performed using GWAMA⁵⁸.

Genetic risk score and cardiovascular outcomes

The gtx package for the R statistical programming language was used to estimate the effect of the SNP-risk score on the response variable in a regression model⁵⁹.

METHODS ONLY REFERENCES

44. Yang, J., Lee, S.H., Goddard, M.E. & Visscher, P.M. GCTA: a tool for genome-wide complex trait analysis. *Am J Hum Genet* 88, 76-82 (2011).
45. Yang, J. et al. Conditional and joint multiple-SNP analysis of GWAS summary statistics identifies additional variants influencing complex traits. *Nat Genet* 44, 369-75, S1-3 (2012).
46. Penninx, B.W. et al. The Netherlands Study of Depression and Anxiety (NESDA): rationale, objectives and methods. *Int J Methods Psychiatr Res* 17, 121-40 (2008).
47. Boomsma, D.I. et al. Netherlands Twin Register: from twins to twin families. *Twin Res Hum Genet* 9, 849-57 (2006).
48. Visscher, P.M., Benyamin, B. & White, I. The use of linear mixed models to estimate variance components from data on twin pairs by maximum likelihood. *Twin Res* 7, 670-4 (2004).
49. Romanoski, C.E. et al. Network for activation of human endothelial cells by oxidized phospholipids: a critical role of heme oxygenase 1. *Circ Res* 109, e27-41 (2011).
50. Koopmann, T.T. et al. Genome-wide identification of expression quantitative trait loci (eQTLs) in human heart. *PLoS One* 9, e97380 (2014).
51. Fairfax, B.P. et al. Innate immune activity conditions the effect of regulatory variants upon monocyte gene expression. *Science* 343, 1246949 (2014).
52. Ramasamy, A. et al. Genetic variability in the regulation of gene expression in ten regions of the human brain. *Nat Neurosci* 17, 1418-28 (2014).
53. Maurano, M.T. et al. Systematic localization of common disease-associated variation in regulatory DNA. *Science* 337, 1190-5 (2012).
54. Welter, D. et al. The NHGRI GWAS Catalog, a curated resource of SNP-trait associations. *Nucleic Acids Res* 42, D1001-6 (2014).
55. Trynka, G. et al. Chromatin marks identify critical cell types for fine mapping complex trait variants. *Nat Genet* 45, 124-30 (2013).
56. Segre, A.V. et al. Common inherited variation in mitochondrial genes is not enriched for associations with type 2 diabetes or related glycemic traits. *PLoS Genet* 6(2010).
57. Pers, T.H. et al. Biological interpretation of genome-wide association studies using predicted gene functions. *Nat Commun* 6, 5890 (2015).
58. Magi, R. & Morris, A.P. GWAMA: software for genome-wide association meta-analysis. *BMC Bioinformatics* 11, 288 (2010).

59. Johnson, T. Efficient Calculation for Multi-SNP Genetic Risk Scores. ASHG 2012 Annual Meeting, poster presentation.